 
   Title: A Randomized Pi[INVESTIGATOR_371081]’s Disease Short Title Holiday Drug or Device Name(s): Polyethylene glycol, neomycin, vancomycin, ciprofloxacin, fluconazole Sponsor: The Broad Medical Research Program at CCFA, the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Secondary Funder: The Children's Hospi[INVESTIGATOR_613021]: 17-014343 Protocol Date: March 13, 2018 Amendment 1 Date: October 19, 2018 Amendment 3 Date: August 16, 2019 Amendment 2 Date: March 1, 2019 Amendment 4 Date: September 20, 2019 Amendment 5 Date: December 16, 2019 Amendment 6: December 20, 2019  Study Principal Investigator: [INVESTIGATOR_371052], DO   Division of Pediatric Gastroenterology The Children’s Hospi[INVESTIGATOR_613022], 14-[ADDRESS_812642], Philadelphia, PA [ZIP_CODE] Phone: [PHONE_12678] email: [EMAIL_11643]   
       
   ii TABLE OF CONTENTS Table of Contents ................................................................................................................... ii	Abbreviations and Definitions of Terms .............................................................................. v	Abstract ................................................................................................................................. vi	Protocol Synopsis ................................................................................................................. vii	Table 1: Schedule of Study Procedures for Intervential Group (Group 1) .................... xii	Table 2: Schedule of study procedures for group 2 ......................................................... xiv	Figure 1: Study Diagram, Group 1 ................................................................................... xiv	1	BACKGROUND INFORMATION AND RATIONALE ........................................................................1	1.1	INTRODUCTION ......................................................................................................................................1	1.2	BACKGROUND AND RELEVANT LITERATURE ........................................................................................1	1.2.1	Inflammatory Bowel Disease: Current Therapi[INVESTIGATOR_613023] ................................1	1.2.2	History of Gut Microbiota-Targeted Therapi[INVESTIGATOR_371061] ..................................................................2	1.2.3	Preliminary Data ..............................................................................................................................3	1.3	SELECTION OF DRUGS AND DOSAGES ...................................................................................................8	1.4	COMPLIANCE STATEMENT .....................................................................................................................8	2	STUDY OBJECTIVES ...............................................................................................................................9	2.1	PRIMARY OBJECTIVE (OR AIM) .............................................................................................................9	2.2	SECONDARY OBJECTIVES (OR AIM) .......................................................................................................9	3	INVESTIGATIONAL PLAN .....................................................................................................................9	3.1	GENERAL SCHEMA OF STUDY DESIGN ..................................................................................................9	3.1.1	Screening & Enrollment Phase ......................................................................................................10	3.1.2	Study Treatment Phase ...................................................................................................................11	3.1.3	Optional Intervention Extension Phase (14 day repeat drug regimen) .........................................12	3.1.4	Follow Up Phase ............................................................................................................................12	3.2	ALLOCATION TO TREATMENT GROUPS AND BLINDING .......................................................................12	3.3	STUDY DURATION, ENROLLMENT AND NUMBER OF SITES ..................................................................12	3.3.1	Duration of Study Participation .....................................................................................................12	3.3.2	Total Number of Study Sites/Total Number of Subjects Projected .................................................13	3.4	STUDY POPULATION ............................................................................................................................13	3.4.1	Group 1: Interventional Group; Participants who have had primary non-response or loss of response to conventional, immunosuppressive treatment ...........................................................................13	3.4.2	Group 2: Observational Group; Participants undergoing clinically indicated PEG lavage in preparation for a GI endoscopy. .................................................................................................................15	4	STUDY PROCEDURES ...........................................................................................................................15	4.1	GROUP 1 PARTICIPANTS ......................................................................................................................15	4.1.1	Screening Visit ................................................................................................................................15	4.1.2	Enrollment Phase (Visit 1) .............................................................................................................16	4.1.3	Study Treatment Phase (Days 1-15 including Visits 2-4): In-person Study Visits .........................16	4.1.4	Daily Surveys ..................................................................................................................................16	4.1.5	Study Visit 2 (Day 5) ......................................................................................................................17	4.1.6	Study Visit 3 (Day 8) ......................................................................................................................17	4.1.7	Study Visit 4 (Day 15) ....................................................................................................................17	4.1.8	Follow-up Phase ............................................................................................................................18	4.1.9	Concomitant Medication ................................................................................................................18	4.1.10	Rescue Medication Administration ............................................................................................19	4.2	GROUP 2 PARTICIPANTS ......................................................................................................................19	4.2.1	Visit 1: Baseline Sample Prior to bowel cleanout ..........................................................................19	4.2.2	Visit 2: Day 5 (+/- 24 hours) after GI endoscopy ..........................................................................19	
       
   iii 4.2.3	Visit 3: Day 12 (+/- 24 hours) after GI endoscopy ........................................................................[ADDRESS_812643] COMPLETION/WITHDRAWAL ................................................................................................19	4.3.1	Early Termination Study Visit ........................................................................................................20	5	STUDY EVALUATIONS AND MEASUREMENTS ............................................................................21	5.1	SCREENING AND MONITORING EVALUATIONS AND MEASUREMENTS .................................................21	5.1.1	Group 1 ..........................................................................................................................................21	5.1.2	Group 2 ..........................................................................................................................................24	5.2	EFFICACY EVALUATIONS ....................................................................................................................24	5.2.1	Diagnostic Tests, Scales, Measures, etc. ........................................................................................24	5.2.2	Fecal calprotectin ..........................................................................................................................25	5.2.3	C-reactive protein (CRP) ...............................................................................................................[ADDRESS_812644] ..........................................................................32	8	SAFETY MANAGEMENT ......................................................................................................................32	8.1	CLINICAL ADVERSE EVENTS ...............................................................................................................32	8.2	ADVERSE EVENT REPORTING ..............................................................................................................32	8.3	DEFINITION OF AN ADVERSE EVENT ...................................................................................................32	8.4	DEFINITION OF A SERIOUS ADVERSE EVENT (SAE) ............................................................................32	8.4.1	Relationship of SAE to study drug or other intervention ...............................................................33	8.5	IRB/IEC NOTIFICATION OF SAES AND OTHER UNANTICIPATED PROBLEMS ......................................33	8.5.1	Follow-up report ............................................................................................................................33	8.6	MEDICAL EMERGENCIES .....................................................................................................................33	9	STUDY ADMINISTRATION ..................................................................................................................34	9.1	TREATMENT ASSIGNMENT METHODS .................................................................................................34	9.1.1	Randomization ................................................................................................................................34	9.1.2	Blinding ..........................................................................................................................................34	9.1.3	Unblinding ......................................................................................................................................34	9.2	DATA COLLECTION AND MANAGEMENT .............................................................................................34	9.3	CONFIDENTIALITY ...............................................................................................................................35	9.4	RECORDS RETENTION ..........................................................................................................................35	9.5	REGULATORY AND ETHICAL CONSIDERATIONS ..................................................................................35	9.5.1	Data and Safety Monitoring Plan ..................................................................................................35	9.5.2	Risk Assessment ..............................................................................................................................36	9.5.3	Potential Benefits of Trial Participation ........................................................................................42	9.5.4	Risk-Benefit Assessment .................................................................................................................42	9.6	RECRUITMENT STRATEGY ...................................................................................................................42	
       
   iv 9.6.1	Group 1 Participants ......................................................................................................................42	9.6.2	Group 2 Participants ......................................................................................................................43	9.7	INFORMED CONSENT/ASSENT AND HIPAA AUTHORIZATION .............................................................43	9.8	PAYMENT TO SUBJECTS/FAMILIES ......................................................................................................45	9.8.1	Gifts ................................................................................................................................................45	10	PUBLICATION .........................................................................................................................................46	11	REFERENCES ..........................................................................................................................................46	 
       
   v ABBREVIATIONS AND DEFINITIONS OF TERMS    AE  Adverse event CBC  Complete blood count CD  Crohn’s disease CDAI  Crohn’s Disease Activity Index CMP  Comprehensive metabolic panel CMV  Cytomegalovirus CRF  Case Report Form CRP  C-reactive protein CTRC  Clinical Translational Research Center EKG  Electrocardiogram ESR  Erythrocyte sedimentation rate FCP  Fecal calprotectin GI  Gastrointestinal HBI  Harvey Bradshaw Index IBD  Inflammatory bowel disease IBDU  Indeterminate colitis ICE  Idiopathic chronic enterocolitis IDS  Investigational Drug Service IRB  Institutional Review Board ITS  Internal Transcribed Spacer LOR  Loss of responsiveness MRN  Medical Record Number PEG  Polyethylene glycol PENN  University of Pennsylvania PCDAI  Pediatric Crohn’s Disease Activity Index PUCAI  Pediatric Ulcerative Colitis Activity Index SAE  Serious adverse event TUNPRC  Tulane University National Primate Center UC  Ulcerative Colitis 
       
   vi ABSTRACT Context:   Recent evidence suggests that the gut microbiota is responsible for the stimulation of the intestinal immune system in Inflammatory Bowel Disease (IBD). Such research indicates that if gut flora plays a role in the pathogenesis of IBD, then perhaps targeting commensal microbes rather than or in addition to the immune system would be more efficacious.  Objectives:  The primary objective is to determine the effect of a novel gut microbiota-targeted therapeutic regimen in the management of active Crohn’s Disease (CD) or IBDU that is refractory to conventional, immunosuppressive therapy. The regimen will deeply modify the gut microbiota and help to treat the gut inflammation associated with IBD, as well as rescue response to biologic or immunomodulator therapi[INVESTIGATOR_014].  Study Design:  This will be a randomized, placebo-controlled, double blind Phase 2a trial.  Setting/Participants: The interventional arm (Group 1) of the study will recruit pediatric patients 6-[ADDRESS_812645] had a loss of response to one or more biologic or immunomodulator therapi[INVESTIGATOR_014]. Group 2 (observational arm) of the study will recruit patients aged 10 and older  who are undergoing a GI endoscopy due to suspi[INVESTIGATOR_613024] (PGA).Study Interventions and Measures:  Only participants in the Group 1 of the study will undergo the study intervention. The study intervention includes a bowel lavage and oral antibiotics (3 days of vancomycin and neomycin followed by 11 days of vancomycin and ciprofloxacin) with or without an antifungal (fluconazole). Measures will be obtained for the evaluation of disease activity (PCDAI), fecal calprotectin, and C-reactive protein. Changes in the composition of the gut microbiota will also be assessed.Group 2 participants will not undergo the study intervention. Group 2 will be an observational group who are undergoing a bowel lavage as part of clinical care. Participants will provide stool samples before and after completing a PEG bowel lavage. Measures will be obtained for the evaluation of fecal calprotectin. Changes in the composition of the gut microbiota will also be assessed. 
 vii      
   PROTOCOL SYNOPSIS Study Title Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease Funder The Broad Medical Research Program at CCFA, the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Clinical Phase Phase II Study Rationale The available evidence suggests that it is the commensal gut microbiota responsible for the stimulation of the intestinal immune system in the inflammatory bowel diseases. Thus, many IBD researchers and providers have questioned the current therapeutic approach.  For instance, if the gut flora plays a role in the pathogenesis of IBD, then perhaps targeting the microbes rather than the immune system, or a combination of the two, would be more efficacious.  Most IBD providers would agree that immune suppressive medications are the most reliable therapi[INVESTIGATOR_613025], but that a therapeutic approach which targets both the gut microbes and the immune system is much more logical based on what we know regarding the pathogenesis of these diseases.   We hypothesize that immune suppressive medications lead to persistent colonization with potentially pathogenic microbes that perpetuate disease chronicity in IBD patients.  Additionally, we hypothesize that host immunosuppression could allow indolent colonizers of the colonic mucosa (symbionts) to behave as pathobionts, thereby [CONTACT_613038] (LOR) to immune suppression. This study will evaluate the efficacy of a novel treatment regimen, employing non-immunosuppressive medications, in the management of refractory CD or IBDU.   Refractory patients include those patients who have experienced LOR or primary nonresponse to an immunomodulator or a biologic.  We will treat patients with a combination of gut microbiota-targeted therapi[INVESTIGATOR_613026] a healthy gut microbiome composition.  We believe that this strategy will both treat the gut inflammation associated with IBD as well as salvage response to immune suppressive therapi[INVESTIGATOR_014].  In addition, the study will determine the effect of PEG lavage alone on fecal calprotectin and gut microbiota in patients with active CD or IBDU.  Study Objective(s) Primary  • To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active CD or IBDU that is refractory to conventional, immunosuppressive therapy.  Secondary • To correlate the effectiveness in reducing bacterial 16S rRNA copy number and fungal 18S rRNA copy number, with the use of the regimen in the primary objective, with improvement of disease activity in patients with CD or IBDU refractory to immunosuppressive therapy. • To determine the relationship between the effectiveness of the proposed therapi[INVESTIGATOR_371056]. • To determine the effect of PEG lavage alone on the microbiome and the fecal calprotectin.  Study Design  Randomized, placebo-controlled, double blind Phase 2a trial Subject Population Key criteria for Inclusion and Exclusion: Group 1-Intervention Participants Inclusion Criteria  1. Parental/guardian permission (informed consent) and if appropriate, child assent. 
 ix      
   2. Males or females 6-18 years of age 3. Current weight >10 kg (or 22 lb) 4. Ability to swallow pi[INVESTIGATOR_3353] 5. Normal kidney function 6. Normal AST, ALT, and alkaline phosphatase 7. Active CD or IBDU defined as PCDAI>30 8. CRP > 15mg/L (or 1.5mg/dL) or fecal calprotectin (FCP)>350mcg/g (within one month of enrollment) 9. Have had primary nonresponse or an initial response for 8 or more weeks, followed by [CONTACT_371086] (LOR) (self-reported worsening of symptoms for at least 7 days), to one or more of the following therapi[INVESTIGATOR_014]*: azathioprine, 6-mercaptopurine, methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab, or ustekinumab *Must be administered at standard, therapeutic dosages  10. Girls who have menses and/or are ³ [ADDRESS_812646] a negative urine/serum pregnancy test and must use an acceptable method of contraception Exclusion Criteria 11. Unwillingness to provide consent 12. Known allergy or intolerance to aminoglycosides or any of the medications used in this study, including medications within the same class 13. Current use of one of more of the following medications: 5-fluorouracil, digoxin, anticoagulants, theophylline, phenytoin, probenecid, duloxetine, clozapi[INVESTIGATOR_050], sildenafil, hydrochlorothiazide, cyclosporine, hypoglycemics, 
 x      
   terfenadine, tacrolimus, rifabutin, midazolam, and voriconazole 14. Known diagnosis of diabetes mellitus 15. Known or suspected stricturing disease producing obstructive symptoms 16. Active Clostridium difficile infection 17. Prolonged QTc interval as seen on enrollment EKG 18. Current use of antibiotics 19. Starting or increasing the dose of an IBD related medication within 4 weeks of screening 20. Participants who may be non-compliant with the study schedules or procedures  Group 2-Observational Arm Participants  Inclusion Criteria 1. Males or females 10 years of age and older.  2.  Patients undergoing a clinical GI endoscopy due to suspi[INVESTIGATOR_613024] (PGA). 3. Undergoing a bowel preparation as part of clinical care. 4. Parental/guardian permission (informed consent) and if appropriate, child assent. Exclusion Criteria 1. Antibiotic use within the past 30 days.  2.   Current presence of an ostomy bag.  3.   Patients undergoing a non- polyethylene glycol 3350 cleanout. 4. Unwillingness to provide informed consent.  5. Parents/guardians or subjects who, in the opi[INVESTIGATOR_689], may be non-compliant with study schedules or procedures.  
 xi      
   Number Of Subjects   [ADDRESS_812647] 6-8 months; Group [ADDRESS_812648] 2 years. Study Phases  For Group 1 participants:  Screening Enrollment Treatment Phase Follow-Up   Efficacy Evaluations Our estimates of efficacy will use a disease activity score (PCDAI) for clinical response (interventional patients only), FCP for mucosal inflammation, and CRP for systemic inflammation (for interventional patients only).  Safety Evaluations For Group 1 participants:  Primary measurements that will be used to assess safety include vital signs, laboratory results, EKG for QTc interval, disease activity scores, and screening for medication side effects and adverse events. Statistical And Analytic Plan The two arms of Group [ADDRESS_812649] descriptive statistics. Categorical variables will be compared using Fisher’s exact test and continuous variables will be compared using the unpaired t-test or Wilcoxon rank sum test if the data are not normally distributed. DATA AND SAFETY MONITORING PLAN The PI [INVESTIGATOR_569417].     
 xii      
       TABLE 1: SCHEDULE OF STUDY PROCEDURES FOR INTERVENTIAL GROUP (GROUP 1)  Screening/ Recruitment Enrollment/ Day  -17 - 0  Day 1 Day 5 Day 8 Day 15 Day 22 Day 29  Day 36-64 (Optional visit) [ADDRESS_812650] for female participants  X          Stool collection for microbiome analysis  X  X X X X X    Stool C. difficile toxin Xc           Rectal swabs for mucosal analysis X Xd   X X  X    FCP Xe    X X X X    CBC (no diff)  X  Blood draw to store for future use X X  X    CMP  X  X X  X    ESR  X  X X  X    CRP  X  X X  X    Serum Cystatin C  X         Infliximab or adalimumab levelf  X         Vancomycin levelg    Xg Xg Xg      PCDAI X (within 1 month) X  X X X  X    EKG  X   X       a. Online Redcap survey completed daily (Day-7 through Day 29). b. Online Redcap survey completed once a week (Day 36 through 6 months). 
 xiii      
   c. C.diff will be performed if no record of negative C.diff within [ADDRESS_812651] within 1 month of enrolment. f. For participants on infliximab or adalimumab. g. Serum vancomycin level will be tested as described in Section 5.1.5.
 page xiv   
   TABLE 2: SCHEDULE OF STUDY PROCEDURES FOR GROUP 2 Study Procedure Screening/ Recruitment (up to Day -1) Day -[ADDRESS_812652] Procedure (+/- 24 hours) Day [ADDRESS_812653] Procedure (+/- 24 hours) Study Visit Visit 0 Day of Bowel Lavage* Day of Procedure* Visit [ADDRESS_812654] review X     Distribution of study supplies X   X  Stool collection for microbiome analysis X   X X Stool collection for FCP analysis  X**   X X *Clinical care procedures **Not completed if participant has a FCP of >350 within 1 month of enrollment available in their clinical chart.    FIGURE 1: STUDY DIAGRAM, GROUP 1  
 

   
   1 1 BACKGROUND INFORMATION AND RATIONALE 1.1 Introduction Recent evidence suggesting that the commensal gut microbiota, or the “gut microbiome,” is responsible for stimulation of the intestinal immune system in inflammatory bowel disease (IBD) has caused many researchers and providers in the field to question current therapeutic approaches.  Though most IBD providers would agree that immunosuppressive medications are currently the most reliable therapi[INVESTIGATOR_014], such research indicates that if gut flora plays a role in the pathogenesis of IBD, then perhaps targeting commensal microbes rather than or in addition to the immune system would be more efficacious.  This protocol seeks to test the hypothesis that a therapeutic approach that deeply alters the composition and bacterial/fungal load of the gut microbiota will be efficacious in patients with refractory Crohn’s Disease (CD) or IBDU who have primary nonresponse or secondary loss of response to conventional, immune suppressive therapi[INVESTIGATOR_014]. This study will evaluate the efficacy of a novel treatment regimen employing non-immunosuppressive medications in the management of refractory CD.  Patients will be treated with a combination of gut microbiota-targeted therapi[INVESTIGATOR_371057][1].  We believe this strategy will both treat the gut inflammation associated with IBD, as well as rescue response to biologic or immunomodulator therapi[INVESTIGATOR_014].    Additionally, this protocol will assess the effect of PEG lavage alone on the microbiome and the fecal calprotectin in patients with active IBDU or Crohn’s disease.   1.2 Background and Relevant Literature 1.2.1 Inflammatory Bowel Disease: Current Therapi[INVESTIGATOR_371058] (IBD), including CD, UC, and IBDU affects approximately 1.5 million Americans and the incidence is increasing worldwide [2].  Current evidence indicates that the pathogenesis of IBD involves an inappropriate and persistent inflammatory response to the gut microbiota in genetically susceptible individuals [3].  In support of this notion, several studies utilizing animal models have shown that the development of intestinal inflammation requires microbial colonization of the gut [4, 5].  Clinical observations of IBD further implicate the role of the commensal gut microbiota, as IBD usually affects intestinal regions with the highest bacterial load, and both fecal diversion and antibiotic treatment can be effective in the management of CD [6, 7]. However, standard treatments for IBD do not focus on restoring immune tolerance to commensal microbes but rather depend on immunosuppression.  Although effective in inducing and maintaining remission for many patients, there is substantial risk of side effects associated with the use of immunosuppressive medications, namely steroids, immunomodulators (e.g., thiopurines and methotrexate) and biologics (e.g., infliximab and adalimumab) [8].  In addition, a significant proportion of patients will experience primary 
   
   2 nonresponse or a loss of response (LOR) to immunosuppression over time in a way that cannot be explained by [CONTACT_371088] [9]. When nonresponse or LOR occurs, providers must escalate dosage or change the treatment medication(s).  Because of the limited number of medications and concern for the exhaustion of non-surgical options, maintaining patients with IBD on an effective medication for as long as possible becomes a priority of clinical care.   1.2.2 History of Gut Microbiota-Targeted Therapi[INVESTIGATOR_613027] [10-12].  For example, IL-[ADDRESS_812655] shown that antibiotics such as neomycin, ciprofloxacin, vancomycin, and metronidazole may both prevent and treat intestinal inflammation [10, 12].  However, the evidence for the effectiveness of antibiotics in the treatment of humans with IBD has historically been less robust.  Within the past several years, two meta-analyses of randomized controlled trials have documented a small but statistically significant benefit of antibiotics to induce remission in both CD and UC [13, 14].  In addition, several studies have now shown that antibiotic combination therapy significantly improves rates of remission and also steroid withdrawal in UC [15-18].   Most notably, Turner and colleagues have recently published their experience using a two- to three-week course of combination antibiotic therapy in pediatric UC and indeterminate colitis refractory to standard immunosuppressive medications [18]. Patients were treated with combination oral amoxicillin, metronidazole, and doxycycline, except in children 2-7 years old where doxycycline was substituted with ciprofloxacin, and in infants under 2 years old where doxycycline was substituted with gentamicin.  In addition, in cases of allergy the allergenic drug was substituted with gentamicin, and in hospi[INVESTIGATOR_371060]. The antibiotic regimen was definitively effective in 7/15 (47%) of patients, inducing complete clinical remission as defined by [CONTACT_371090] (PUCAI).  For the patients defined as primary responders (n=9), i.e., clinical remission at three weeks after initiating antibiotic therapy, reduction in CRP and PUCAI were statistically significant.  Finally, all patients repeatedly tested negative for fecal C. difficile and bacterial cultures indicative of developed resistance. Only one patient tested positive for CMV and was subsequently treated with ganciclovir.  These findings demonstrate the potential efficacy of an antibiotic therapeutic strategy in the treatment of refractory IBD.   Antifungals In addition to the bacterial component, there appears to be a relationship between IBD and the fungal gut microbiota. The authors of a recent study demonstrated that mice lacking Dectin-1, a C-type leptin receptor that recognizes β-glucans in the fungal cell wall, had increased susceptibility to chemically induced colitis due to their altered immunological responses to indigenous fungi [19]. Significantly, a polymorphism in the gene encoding Dectin-1 (CLEC7A) was found to be associated with a severe form of ulcerative colitis in 
   
   3 humans [19]. A connection between high dietary concentrations of yeast and increased disease activity in patients with CD has also been suggested [20].    In terms of fungal-targeted therapi[INVESTIGATOR_371061], preliminary evidence suggests that fluconazole treatment may reduce intestinal inflammation in animal models of colitis and in patients with IBD [21]. We recently demonstrated a significant difference in the composition of the fungal microbiota in pediatric patients with IBD as compared to healthy controls [2], further suggesting a relationship between fungi and the pathogenesis of IBD.  Bowel Lavage Given the potential role of the gut microbiota in the pathogenesis of IBD, therapi[INVESTIGATOR_371062] (GI) tract have been suggested. For example, in the 1980’s, intestinal lavage with normal saline was studied in patients hospi[INVESTIGATOR_371063]. A small, controlled study demonstrated reduction in disease severity and also duration of hospi[INVESTIGATOR_059] [23, 24]. Failure to further develop bowel lavage as an independent therapeutic option is likely secondary to advancements in pharmacological therapi[INVESTIGATOR_014]. Recent evidence has indeed shown that bacterial diversity in the gut is significantly decreased following colonoscopy preparations [25].  It is unknown the effects of PEG lavage on the gut microbiome composition and FCP. It is expected that the effect of the PEG lavage on gut microbiota composition and fecal calprotectin will be comparable across patients who have been diagnosed with inflammatory bowel disease. 1.2.3 Preliminary Data Effectiveness of Antibiotics in Mouse Models versus Humans, What’s the Difference? The observation that antibiotics as currently used have only modest efficacy in the treatment of CD and UC represents a challenge to the notion that antimicrobials could be used to deplete the microbiota in patients with IBD. One possible explanation is that the use of antibiotics in animal models is more effective in reducing intestinal bacterial load in mice than in humans. Indeed, in preliminary data [3], we show that two specific oral antibiotics dramatically reduce bacterial load by [CONTACT_7809] 4 logs in mice within 72 hours, as quantified by 16S gene copy number.   
   
   4 
  We believe that an antibiotic therapeutic strategy capable of significantly reducing bacterial load in patients with CD will show greater levels of efficacy in the treatment of active disease than in previously reported studies [26-28]. Additionally, based on data suggesting the potential importance of gut fungi in IBD, we hypothesize that to focus exclusively on gut bacterial load may represent a missed opportunity. Efficacy of the Holiday Regimen for Treatment of Chronic Enterocolitis in Rhesus Macaques (Macaca mulatta) Idiopathic chronic enterocolitis (ICE) is one of the most significant causes of morbidity and mortality in captive nonhuman primates and remains a diagnostic and therapeutic challenge for veterinarians working with these species.  Current evidence suggests that ICE is a multifactorial disease involving perturbations in gastrointestinal bacterial populations, as well as the response of the host immune system to these changes [29].  Our group is currently collaborating with Tulane University National Primate Center (TUNPRC) on a study where rhesus macaques with ICE and a negative stool infectious work-up (n=6 at present) were treated with an anti-microbial regimen similar to the one proposed here.  The animals receive the following regimen: 125 mg total vancomycin hydrochloride four times daily, 50 mg/kg neomycin twice daily, and fluconazole 2 mg/kg twice daily.  Therapy was administered for a total of [ADDRESS_812656] experienced no signs of diarrhea since completion of the treatment protocol.  Soft stool was observed for one day in the remaining two monkeys since completion of treatment, with normal stool observed on other days for both animals.  Based upon daily observations of mentation/behavior, activity level, and appetite as well as pre-treatment and intra-treatment CBC and serum chemistries, this treatment regimen was well-tolerated by [CONTACT_371092]. Efficacy of Combination Antibiotic Therapy for Refractory IBD at CHOP 
Figure 2: Time course of 16S rRNA gene copy number during oral antibiotic treatment (14 days of vancomycin plus neomycin) and upon discontinuing antibiotics on day 15 compared to control. 
   
   5 Since the paper by [CONTACT_613039] [18] was presented at a national meeting in 2014, physicians within the CHOP Center for Inflammatory Bowel Disease have been utilizing a combination antibiotic approach clinically for patients with IBD refractory to standard therapy.  As a means of preliminary efficacy evaluation, a retrospective study (CHOP IRB #15-011806) was performed to review CHOP’s experience treating refractory IBD with combination antibiotic therapy.  Information collected included patient demographics, disease characteristics, immunotherapy history, indication for antibiotic therapy, and type, dosage, and duration of antibiotics prescribed.  Eligible patients were ages 3-21 and prescribed treatment with three or more oral antibiotics concomitantly for the treatment of IBD.  Clinical outcomes were evaluated based on changes in disease activity, as measured by [CONTACT_371094]’s Disease Activity Index (PCDAI) in participants with CD, or the Pediatric Ulcerative Colitis Activity Index (PUCAI) in patients with UC or indeterminate colitis, at the time of initiation of combination antibiotic therapy and at multiple subsequent time points.  Disease morbidity outcomes were additionally measured, including referral to and/or scheduling of surgery, as well as escalation of therapy to an experimental medication.  The incidence of adverse reactions during and following combination antibiotic therapy was also assessed.   Of the enrolled patients (n=14), four participants had CD (29%) and the remainder had UC or indeterminate colitis (IBDU) (Table 1).  In [ADDRESS_812657] immunosuppressive therapi[INVESTIGATOR_371064].  Participants were prescribed combination antibiotic therapy for an average of 29.5 days (range 9-71).  TABLE 1: PEDIATRIC IBD PATIENTS TREATED AT CHOP WITH COMBINATION ANTIBIOTICS Case Number Agea IBD Type LOR to Medicationsb Antibiotic Regimenc Duration in Days Surgery Referral Experimental Therapyd Rescue of Response 1 13.2 UC IFX+MTX MAC 14 Cancelled No escalation IFX+MTX 2 12.3 UC IFX MADV 71 Delayed (96 days) n/a IFX 3 16.4 CD IFX+MTX, ADA+MTX MCV 23 n/a No escalation ADA+MTX 4 10.8 CD IFX+MTX MAC 9 Proceeded n/a n/a 5 13.1 IBDU IFX, ADA+MTX MAC 24 Cancelled n/a ADA+MTX 6 15.7 CD IFX+MTX MACV 28 n/a Escalation n/a 7 13.6 UC IFX+MTX MAC 21 n/a n/a n/a 8 18.5 UC IFX+MTX MAC 59 Cancelled No escalation n/a 
   
   6 9 11.5 UC IFX RCV 35 n/a n/a IFX+MTX 10 10.7 IBDU IFX+MTX, ADA MCV 19 Delayed (22 days) No escalation n/a 11 6.5 CD IFX+MTX, ADA+MTX MCV 36 n/a n/a ADA+MTX 12 16.1 CD IFX MCDV 31 n/a No escalation IFX+MTX 13 12.3 UC n/a MCV 21 n/a n/a n/a 14 10.4 UC IFX MCDV 22 Cancelled n/a n/a          aAge at initiation of antibiotic therapy  bAll demonstrated LOR; IFX=infliximab monotherapy, IFX+MTX=IFX plus methotrexate dual therapy, ADA+MTX=adalimumab plus methotrexate dual therapy cA=amoxicillin, C=ciprofloxacin, D=doxycycline, M=metronidazole, R=rifaximin, V=vancomycin  dReferral or discussion of eligibility screening for vedolizumab (Entyvio) or ustekinumab (Stelara)   Because of the limitations inherent to the review of existing medical records, disease activity scores at all study time points were not available for each participant.  However, for those participants with available data, PUCAI and PCDAI scores showed decreases in disease activity both two weeks post-initiation and post-completion of their prescribed antibiotic combination regimen. There were four documented adverse reactions that occurred during the course of therapy or shortly following therapy termination.  All were mild and only one was probably related to the medication regimen (black, hairy tongue); all resolved without sequelae.  In addition, there were two severe and one life-threatening adverse event; however, all occurred two weeks after termination of therapy and based on clinical expertise were unlikely related to the antibiotic therapy.  Only one additional event was possibly related to the prescribed antibiotic therapy – a vaginal yeast infection that occurred four weeks post-termination of therapy and which also resolved without sequelae. Efficiency of Combination Antibiotic Therapy for Refractory IBD at PENN Lindsey Albenberg, DO is performing a clinical trial in adults with a similar IRB-approved protocol at the University of Pennsylvania, which has shown potential for benefit and safety of the drug regimen. The primary endpoint in the Penn protocol is the change in disease activity, as measured by [CONTACT_613040] (HBI) score, and FCP concentration, between the enrollment visit and Day 15. A reduction of HBI by [ADDRESS_812658] antimicrobial therapy. This participant also had normalization of his fecal calprotectin from enrollment to day 15. The second two participants had decreases in the 
   
   7 HBI from enrollment to day 15. However, neither of these participants had a significant change in fecal calprotectin. One of these participants developed acute diarrhea on day 17. Stool infectious studies (including C. difficile) were negative. It was determined that the worsening of his diarrhea was related to progression of his already very severe CD. The fourth participant also demonstrated a significant improvement in HBI as well as normalization of the fecal calprotectin and this individual is still in the follow-up phase. The fifth participant is currently in the intervention phase, but this participant had an improvement in his HBI and normalization of his fecal calprotectin by [CONTACT_4475] 8. Of note, there was one serious adverse event, but it was unrelated to the study procedures. There have been no other serious adverse events. We are observing very significant reductions in fecal calprotectin from baseline to day [ADDRESS_812659] the response has been (better response than expected), we want to be sure that the reduction in calprotectin truly represents healing of the tissue versus the PEG lavage flushing out the neutrophils. This will be examined in Group 2.  Table 2 shows change in HBI after completing the two week study regimen. These findings demonstrate the potential for benefit of the therapy proposed in this protocol.  TABLE 2: CHANGE IN HARVEY BRADSHAW INDEX (HBI) & DISEASE CATEGORY FOR HOLIDAY PARTICIPANTS AT PENN Participant Number HBI at Enrollment HBI on Day 15 Number of Points Decreased  Clinically Significant (Y/N)* Disease Category at Enrollment Disease Category on Day 15 [ZIP_CODE] 11 3 8 Y Moderate Remission [ZIP_CODE] 13 7 5 Y Moderate Mild [ZIP_CODE] 9 5 4 Y Moderate Mild [ZIP_CODE] 8 4 4 Y Moderate Remission [ZIP_CODE] 7 5 2 N Mild Mild *A reduction of HBI by [ADDRESS_812660] the hypothesis that the gut microbiota is fundamentally involved in the perpetuation of CD that is refractory to conventional strategies and that a strategy that dramatically alters the composition and/or biomass of the gut microbiota (both bacteria and fungi) will lead to clinical improvement and reduction of inflammation.   
   
   [ADDRESS_812661] a “Holiday” from gut microbes that may be perpetuating the inflammatory response.  We will attempt to reduce the microbial load in the gut through an intestinal lavage followed by [CONTACT_69506]-term (14 days) treatment with broad-spectrum antibiotics with or without an antifungal.  The intestinal lavage protocol was chosen based on the standard bowel cleanse protocol utilized at Children’s Hospi[INVESTIGATOR_613028] [30].  In the animal study above (Figure 1) demonstrated ability to significantly reduce 16S rRNA gene copy number with a combination of two oral antibiotics – neomycin and vancomycin.  This protocol has been adapted for human use because of the risk of ototoxicity, which is associated with long-term neomycin therapy. Thus, using neomycin only for the first three days, and then neomycin will be replaced with ciprofloxacin. Ciprofloxacin will be an appropriate replacement as it is well known to be deeply disruptive to the gut microbiota [4]. For the antifungal, the study will use fluconazole, which is used to treat a variety of fungal infections, because it is considered to be a safer option than other systemic antifungals such as amphotericin.   Animal studies have shown that the 16S rRNA gene copy number decreases after three days of therapy and returns to baseline five days after antibiotics are discontinued. Fourteen (14) days of therapy was chosen for this study so that there would be continued suppression of bacterial load to allow sufficient time for healing of the gastrointestinal tract. This protocol chose standard pediatric dosing for the treatment of systemic or gastrointestinal infections (see Section 7.1 for dosages). Participants in this study will not be required to stop any prior medications (including immunosuppressive medications), with the exception of probiotics and antibiotics. If potential participants are on prescribed antibiotics related to their IBD, they are required to stop those antibiotics in order to participate in this study. If potential participants are on antibiotics for a non-IBD related reason, they will be required to complete their current course before being enrolled in this study. Furthermore, participants already on steroids as part of their IBD regimen will be required to maintain their dosage and regimen during the 14 days (Days 1-14) of the study drug intervention. If steroid dosage is increased during the [ADDRESS_812662] started rescue therapy and study drugs will be stopped. 1.4 Compliance Statement This study will be conducted in full accordance all applicable Children’s Hospi[INVESTIGATOR_158737] 45 CFR 46, 21 CFR Parts 50, 54, 56, 312, 314 and 812 and the Good Clinical Practice: Consolidated Guideline approved by [CONTACT_5787] (ICH). All epi[INVESTIGATOR_48478]. The investigators will perform the study in accordance with this protocol, will obtain consent and assent, and will report unanticipated problems involving risks to subjects or others in accordance with The Children’s Hospi[INVESTIGATOR_137069]. Collection, recording, and reporting of data will be 
   
   [ADDRESS_812663] experienced LOR or nonresponse to an immunomodulator or a biologic.  LOR is defined as patients who were doing well initially on an appropriate dosage of an immunomodulator or a biologic and subsequently developed increased disease activity.  We will treat patients with a combination of bowel lavage and oral antimicrobials.  We hypothesize that this strategy will both treat the gut inflammation associated with IBD as well as salvage response to therapy. 2.1 Primary Objective (or Aim) The primary objective of this study is to determine the efficacy of a novel gut microbiota-targeted therapeutic regimen, comprised of a bowel lavage and oral antibiotics with or without an antifungal, in the management of active CD or IBDU that is refractory to conventional, immunosuppressive therapy. 2.2 Secondary Objectives (or Aim) The secondary objectives are to: • Correlate effectiveness in reducing bacterial 16S and fungal 18S rRNA gene copy number, by [CONTACT_371095], with improvement in disease activity for patients with CD or IBDU refractory to immunosuppression.  • Determine the relationship between the effectiveness of the proposed therapi[INVESTIGATOR_371056].  • To determine the effect of PEG lavage alone on the microbiome and the fecal calprotectin. 3 INVESTIGATIONAL PLAN 3.1 General Schema of Study Design “Holiday” will be a randomized, placebo controlled, double blind Phase 2a trial. Participants will be enrolled into one of two groups. Group [ADDRESS_812664] to enroll 60 participants to produce 20 evaluable participants in Group 1 and 15 evaluable participants in Group 2.A similar IRB-approved protocol is being conducted in adults at the University of Pennsylvania. The ultimate enrollment goal between both sites is 30 adults and 30 children (Group 1 only) to yield [ADDRESS_812665] demonstrated nonresponse or LOR to immunosuppressive therapy, and may be facing escalation of therapy or even surgery.  Group 2 recruitment will target patients undergoing clinically indicated PEG lavage in preparation for a GI endoscopy.  Once enrolled, participants in Group 1 will be treated with bowel lavage and oral antibiotics with or without an antifungal over a period of 14 days. Clinical efficacy will be assessed at defined time points through scoring on the Pediatric Crohn’s Disease Activity Index (PCDAI) and the Short Crohn’s Disease Activity Index (sCDAI), the fecal calprotectin (FCP), a clinical marker of intestinal inflammation, and the C-reactive protein (CRP), a marker of systemic inflammation. At the stool collection time points, the composition of the gut microbiota will also be determined using 16S gene qPCR, 18S gene qPCR, 16S gene sequencing, and internal transcribed spacer (ITS) gene sequencing to determine effects on bacterial and fungal load and microbiota composition.   Participants in Group [ADDRESS_812666] of the bowel lavage alone on disease activity (determined via fecal calprotectin levels) and composition of gut microbiota (determined via 16S gene qPCR, 18S gene qPCR, 16S gene sequencing, and ITS gene sequencing) will be assessed. 16S gene qPCR determines bacterial load. 18S gene qPCR determines fungal load. 16S gene sequencing determines bacterial microbiota composition. ITS gene sequencing determines fungal microbiota composition.   3.1.1 Screening & Enrollment Phase Potential participants will be identified through medical chart review, clinic schedules, inpatient lists, as well as physician referrals. Families will be contact[CONTACT_426] a research team member and informed consent will be obtained.  For prospective Group 1 participants, a  REDCap Screening Questionnaire will be completed to confirm eligibility, and an enrollment visit will be scheduled. Participants will be given study supplies necessary for appropriate specimen collection. For prospective Group 2 subjects, consent will be obtained over the phone. [IP_ADDRESS] Group 1(Interventional Group)  For Group 1 participants, a verbal screening consent form will be obtained before collecting screening information. Once verbal consent is obtained, potential participants will be sent a REDCap Screening Questionnaire. Participants who seem to meet all inclusion criteria (see Section [IP_ADDRESS]) will be scheduled for an enrollment visit and will be given study supplies. The screening consent will allow the subject to complete the screening questionnaire and provide samples at their first visit. Written informed consent, and assent when appropriate, will be obtained before undergoing any other study procedures.  The study will be explained to each participant and their legal guardian when they come to the study site.  If the subject and/or guardian agrees to participate, they will sign the written consent form.The enrollment visit will include a physical examination to determine eligibility based on clinical 
   
   [ADDRESS_812667] menses and/or are > [ADDRESS_812668]. All participants will undergo electrocardiogram (EKG) to assess QTc interval at baseline. Participants and their parents will also be asked to complete 7 days of an online “Daily Survey” through REDCap to record their baseline symptoms before starting any study drug.  [IP_ADDRESS] Group 2 (Observational Group)   For Group 2 participants, a verbal informed consent form will be obtained before collecting a baseline stool sample and starting their clinically indicated bowel preparation. We will target patients who had a clinical disease activity score, physician global assessment, or laboratory values suggestive of ongoing active inflammation. If a clinical fecal calprotectin level greater than or equal to 350 mcg/g is not available within a month prior to enrollment, the baseline stool sample will be tested for fecal calprotectin level.  . If the baseline fecal calprotectin is ³350 mcg/g and if the patient’s primary GI does not intend to start the patient on a corticosteroid or biologic within the 7 days following the procedure, subjects will then provide additional stool samples at time points 5 days and 12 days after their clinically-indicated procedure. These stool collection time points align with those of Group 1 participants, relative to their PEG lavage.  3.1.2 Study Treatment Phase  For Group 1 participants who are fully eligible, medications will be dispensed from The University of Pennsylvania’s Investigational Drug Services (Penn IDS) and shipped to the participant’s home address. There will be no more than 17 days between the enrollment visit and the start of the intervention phase. The antimicrobial regimen will include 3 days of vancomycin and neomycin followed by 11 days of vancomycin and ciprofloxacin. Participants will also be randomized 1:1 in a double-blinded fashion to fluconazole or placebo for 14 days. See Section 7.1 for details about dose, frequency and duration of all study drugs.  On Day 2, participants will also undergo a bowel preparation with polyethylene glycol (PEG) 3350. On this day, the diet will be limited to clear liquids. There will be no other dietary modifications during the course of the study. 
   
   12 On Days 1-14, participants and/or their parent/guardian will record their symptoms daily through a secure, web-based portal (REDCap).  This information will be used to calculate the sCDAI score.  In– person study visits will take place on days 5, 8, and 15. The indicated clinical and laboratory parameters will be assessed at the time of these visits.  There is a +/- [ADDRESS_812669] occur. 3.1.3 Optional Intervention Extension Phase (14 day repeat drug regimen) Group 1 participants who achieve clinical response (reduction of PCDAI by 15 or more points) or clinical remission (PCDAI <15) to the study intervention at Day 15, but have relapsed (PCDAI > 30 or sCDAI > 20) between days 30 and 64 (2 months), will be offered the option to repeat the 14 day study regimen. Once the study team is aware of a participant’s disease relapse, the participant’s symptoms will be observed for 2 weeks through the survey before starting their extension phase to confirm relapse. Participants who repeat the regimen will not require rescreening or a repeat enrollment visit. To reduce the risk of a prolonged QTc interval, the repeated regimen will exclude fluconazole/ placebo. The PEG lavage will also be excluded. An additional telephone visit (visit 6.1) will be conducted. This visit will take place at the end of the extension phase. All participants will have a 3 month visit (visit 7) and the last study visit for all participants will be at [ADDRESS_812670] on Day 29.  The indicated clinical and laboratory parameters will be assessed at the time of these visits (See Table 1, Study Schedule of Procedures). There is a +/- 3 day window for these two visits (Day 22 and 29). Finally, telephone follow-ups will occur at 3 months and 6 months following the intervention phase.  There will be a 14-day window for the 3 month and 6 month follow-up telephone visits. 3.2 Allocation to Treatment Groups and Blinding Within Group 1, participants will be randomized to one of two arms, one which will be receiving fluconazole in addition to antibiotics and one which will receive placebo. The randomization schedule will be generated by [CONTACT_371109]. Neither the participant, the study team, nor the clinical site personnel will know the treatment group to which any participant is randomized. 3.3 Study Duration, Enrollment and Number of Sites 3.3.1 Duration of Study Participation [IP_ADDRESS] Group 1 Participants The study duration per Group 1 participant will be approximately 6-8 months, with up to 30 days for screening (from telephone verbal consent to the enrollment visit), 2 weeks for the intervention phase, and up to 6 months for the follow-up phase.   
   
   13 Participants who meet criteria and opt to undergo the extension phase of the antimicrobial regimen will prolong their participation in the study by [CONTACT_3450] 2 weeks.  [IP_ADDRESS] Group 2 Participants The study duration per Group 2 participant could be up to 2 months.   3.3.2 Total Number of Study Sites/Total Number of Subjects Projected The study will be performed at one site, The Children’s Hospi[INVESTIGATOR_6684]. A similar IRB-approved protocol is being conducted in adults at the University of Pennsylvania. The research will include outcome data from the Penn protocol. Data from these individuals will not be included in the enrollment numbers for this study and research activities under the Penn protocol will not be reported as part of the continuing review. We expect to enroll 60 participants to produce 20 evaluable participants in Group 1 and 15 evaluable participants in Group 2. 3.4 Study Population 3.4.1 Group 1: Interventional Group; Participants who have had primary non-response or loss of response to conventional, immunosuppressive treatment [IP_ADDRESS] Inclusion Criteria —  1. Parental/guardian permission (informed consent) and if appropriate, child assent. 2. Males or females 6-18 years of age 3. Current weight >10 kg (or 22 lb) 4. Ability to swallow pi[INVESTIGATOR_3353] 5. Normal kidney function, defined by [CONTACT_67889] >90 mL/min/1.73m3, estimated using serum cystatin C, creatinine, BUN, and height in the combined comprehensive eGFR equation.  6. Normal AST, ALT, and alkaline phosphatase, < 1.5 than the upper limit of normal for the reference range for the child’s age, according to CHOP lab reference ranges. 7. Active CD or IBDU defined as PCDAI>30 *Patients who have a partial PCDAI  of at least 20, including only the subjective reporting of symptoms over the past week (see Section 5.2.1), will be considered eligible for scheduling of an enrollment visit and will only be actively enrolled with a definite PCDAI score of 30 or above, inclusive of the physical examination and abdominal mass component.  8. CRP >15mg/L (or 1.5mg/dL) or fecal calprotectin (FCP) > 350mcg/g (within one month of enrollment) 9. Have been treated with one of the following therapi[INVESTIGATOR_014]** for at least 8 weeks with primary nonresponse or an initial response, followed by [CONTACT_371101] (self-reported 
   
   14 worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine, methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab, or ustekinumab If taking steroids, dose must be stable for at least 2 weeks prior to screening **These medications must have been administered at standard, therapeutic dosages. 10. Girls who have menses and/or are ³ [ADDRESS_812671] a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study. [IP_ADDRESS] Exclusion Criteria —  1. Unwillingness to provide informed consent  2. Allergy or intolerance to aminoglycosides or any of the medications used in this study, including medications within the same class 3. Current use of one or more of the following medications: 5-fluorouracil, digoxin, anticoagulants, theophylline, phenytoin, probenecid, duloxetine, clozapi[INVESTIGATOR_050], sildenafil, hydrochlorothiazide, cyclosporine, hypoglycemics, terfenadine, tacrolimus, rifabutin, midazolam, and voriconazole 4. Known diagnosis of diabetes mellitus 5. Known or suspected stricturing disease producing obstructive symptoms 6. Active Clostridium difficile infection 7. Baseline QTc interval on EKG as follows: a. 3-5 yo: >412ms in males or >417ms in females b. 5-8 yo: >411ms in males or >409ms in females c. 8-12 yo: >407ms in males or >414ms in females d. >18 yo: > 430ms in males or > 450ms in females 8. Current use of antibiotics 9. Starting or increasing the dose of a IBD related medication within 4 weeks of screening including: e. Azathioprine or 6-mercaptopurine (6MP) f. Infliximab, adalimumab, certolizumab, or golimumab g. Natalizumab, vedolizumab, or ustekinumab 
   
   15 h. Methotrexate i. Any 5-ASA compound (e.g. Lialda, Asacol, etc) j. Prednisone, budesonide or other steroids delivered orally or rectally 10. Participants who, in the opi[INVESTIGATOR_871], may be non-compliant with study schedules or procedures 3.4.2 Group 2: Observational Group; Participants undergoing clinically indicated PEG lavage in preparation for a GI endoscopy.  [IP_ADDRESS] Inclusion Criteria —  1. Males or females 10 years of age and older.   2.  Patients undergoing a clinical GI endoscopy due to suspi[INVESTIGATOR_613024] (PGA). 3. Undergoing a bowel preparation as part of clinical care. 4. Parental/guardian permission (informed consent) and if appropriate, child assent. [IP_ADDRESS] Exclusion Criteria —  1. Antibiotic use within the past 30 days.   2. Current presence of an ostomy bag.  3.   Patients undergoing a non- polyethylene glycol 3350 cleanout. 4. Unwillingness to provide informed consent.  5. Parents/guardians or subjects who, in the opi[INVESTIGATOR_689], may be non-compliant with study schedules or procedures. Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations of these criteria must be reported in accordance with IRB Policies and Procedures.  4 STUDY PROCEDURES 4.1 Group 1 Participants 4.1.1 Screening Visit Screening visit will include: • Informed consent  • Email or complete screening questionnaire  • Schedule enrollment visit  • Distribute study supplies 
   
   16  4.1.2 Enrollment Phase (Visit 1) Eligible participants will be seen by a study team investigator and study coordinator at the enrollment visit.  The written informed consent form may be signed at this visit if not already completed.  Enrollment will include: • Written informed consent & assent (if applicable) • Review and documentation of eligibility criteria  • Obtain collected stool sample for analysis of microbiome  o If no record of negative C. difficile toxin  within [ADDRESS_812672] fecal calprotectin • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for PCDAI • Rectal swabs (2) for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, CRP, ESR, serum cystatin C, biologic levels if applicable with extra stored for future use) • Urine pregnancy test for female participants (if applicable) • EKG • Medication education • Distribution of Gatorade (and a pi[INVESTIGATOR_39179]) • Distribution of supplies  4.1.3 Study Treatment Phase (Days 1-15 including Visits 2-4): In-person Study Visits Day [ADDRESS_812673] the participant to start taking study drugs on the upcoming Monday, Thursday, or Friday, in order to enhance compliance and ensure that in-person study visits do not fall on weekends.  4.1.4 Daily Surveys The participant and/or their parent/guardian will be asked to complete an online survey through REDCap asking a variety of questions to monitor disease activity. Participants and their parent/guardian will be prompted to identify any concerns including medication side effects and/or worsening of symptoms.  This survey will be completed as listed in Table 1, Schedule of Study Procedures. Survey responses will be monitored by [CONTACT_371116] a regular basis. If surveys are not completed as scheduled, the coordinator may contact [CONTACT_613041].  If a participant is enrolled in the study who does not have daily access to the internet and/or email, a daily survey paper diary will be provided to them. In order to ensure compliance for 
   
   17 this group, they will be required to ship the completed paper surveys to the study team on a weekly basis. Shippi[INVESTIGATOR_371067]. 4.1.5 Study Visit 2 (Day 5) The visit will include: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom history for PCDAI • Blood sample (vancomycin level, with extra stored for future use to evaluate metabolomics and neomycin levels) • Obtain stool sample • Adverse event assessment (see Section 8) • Study drug compliance assessment • Update current medications log • Daily Survey  • Distribution of supplies 4.1.6 Study Visit 3 (Day 8) The visit will include: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for PCDAI • EKG • Rectal swab for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, CRP, ESR with extra stored for future use and vancomycin level, if applicable) • Obtain stool sample  • Adverse event assessment (see Section 8) • Study drug compliance assessment • Update current medications log • Daily Survey  • Distribution of supplies 4.1.7 Study Visit 4 (Day 15) The visit will include: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for PCDAI • Rectal swab for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, CRP, ESR with extra stored for future use and vancomycin level, if applicable) • Collect stool sample  
   
   18 • Adverse event assessment (see Section 8) • Study drug compliance assessment and collect any unused study drug • Update current medications log • Daily Survey  • Distribution of supplies 4.1.[ADDRESS_812674]-treatment, participants and/or their parent/guardian will continue to record symptoms weekly in REDCap. Telephone follow-up will occur at 3 months and 6 months. [IP_ADDRESS] Telephone Follow-Up: Visit 5 (Day 22) A telephone follow-up will be conducted on Day 22 (+/- 3 days). During the telephone session, questions will be asked to assess the general state of the participant’s IBD and their current medication regimen. The participant’s electronic medical record will be reviewed. Any recent surgeries, hospi[INVESTIGATOR_602], and C difficile test results since their last study visit will be recorded. Participants and their parent/guardian will be reminded to ship or bring in a stool sample. [IP_ADDRESS] Study Visit 6 (Day 29) The visit will be conducted on Day 29 (+/- 3 days). The visit will include: • Vital signs • Anthropometric measurements • Physical exam, including CD disease symptom assessment for PCDAI • Rectal swab for mucosally-associated microbiome analysis • Blood sample (CBC, CMP, CRP, ESR with extra stored for future use) • Collect stool sample  • Adverse event assessment (see Section 8) • Study drug compliance assessment • Update current medications log • Daily Survey  [IP_ADDRESS] Telephone Follow-Ups: 3 Months & 6 Months Telephone follow-up will also occur at 3 months and 6 months (+/- 2 weeks). Questions will be asked to assess the general state of the participant’s IBD and their current medication regimen. The participant’s electronic medical record will be reviewed. Any recent surgeries, hospi[INVESTIGATOR_602], and C difficile test results since their last study visit will be recorded. 4.1.[ADDRESS_812675] be discontinued prior to the start of the 
   
   19 intervention phase (day 1-14). If potential participants are on prescribed antibiotics related to their IBD, they will be required to stop those antibiotics in order to participate in this study. If potential participants are on antibiotics for non-IBD related reasons, they will be required to complete their current course before enrolling in this study. Participants already on steroids as part of their IBD regimen will be required to maintain their dose and regimen during the 14 days (Days 1-14) of the study drug intervention. If steroid dosage is increased during the [ADDRESS_812676] started rescue therapy and study drugs will be stopped. 4.1.10 Rescue Medication Administration If a participant’s condition worsens during the course of the study, the PI, in conjunction with the participant’s primary provider, will make a decision on whether or not to withdraw the participant from the study.  If the participant receives rescue medication(s) during Days 1-14 of the study, the study drugs will be stopped and they will be considered a non-responder. Participants will be followed until the end of the 6 month time point of the study schedule.  4.2 Group 2 Participants 4.2.1 Visit 1: Baseline Sample Prior to bowel cleanout • Obtain informed consent • Medical Record Review • Distribution of study supplies • Collect stool sample  4.2.2 Visit 2: Day 5 (+/- 24 hours) after GI endoscopy • Medical Record Review • Collect stool sample  • Distribute supplies for next sample collection  4.2.3 Visit 3: Day 12 (+/- 24 hours) after GI endoscopy  • Medical Record Review • Collect stool sample    4.[ADDRESS_812677] Completion/Withdrawal Participants may withdraw from the study at any time without prejudice to their clinical care.  They may also be discontinued from the study at the discretion of the PI [INVESTIGATOR_613029], AEs, lack of response, reasons of safety, administrative reasons and/or need for rescue medication during the enrollment or intervention phase.  Participants who require rescue medication or surgery after completion of the intervention regimen (Day 15 or later) will continue to be followed by [CONTACT_371119]. If a subject withdraws from the study all research samples and data collected prior to withdraw will remain part of the study.   It will be documented whether or 
   
   20 not each participant completes the clinical study. If the PI [INVESTIGATOR_613030], related adverse events after the participant completes or withdraws from the study, they will be recorded in the adverse event log of the study and to the IRB (when applicable). 4.3.[ADDRESS_812678]. 
   
   21 5 STUDY EVALUATIONS AND MEASUREMENTS 5.1 Screening and Monitoring Evaluations and Measurements 5.1.1 Group 1 [IP_ADDRESS] Medical Record Review Include a listing of the variables that will be abstracted from the medical chart (paper or electronic). • Date of birth • MRN • Mailing address • Email address • Telephone number • Sex • Race • Height • Weight • IBD history (including date of diagnosis, and disease location) • Prior use of medications • Current medications • Medication allergies • Surgical history (including all surgeries regardless of relation to IBD) • Co-morbid medical conditions • History of stricturing or fistulizing disease • Interview with participant (such as bowel frequency, abdominal pain, general well-being) • Physical examination • Laboratory tests (including ESR, CRP, albumin, hematocrit, hemoglobin, fecal calprotectin, stool C. difficile toxin, drug levels for biologics) [IP_ADDRESS] Physical Examination A physical examination will be performed in order to calculate the PCDAI at all in-person study visits for Group 1 participants. A study investigator will document whether there is an abdominal mass (0=no tenderness, no mass, 5= tenderness, no mass without tenderness, 10 = tenderness, involuntary guarding, definite mass). A study investigator will also document any extraintestinal manifestations of disease, including arthralgia, uveitis, erythema nodosum, aphthous ulcers, Pyoderma gangrenosum, anal fissure, new fistula, and/or abscess. Documentation may be completed in EPIC. [IP_ADDRESS] Vital Signs Oral temperature will be obtained using a digital thermometer.  Heart rate and blood pressure will be obtained using an automated device while the patient is seated.  Height and weight will also be obtained as listed in Table 1, Schedule of Procedures. 
   
   22 [IP_ADDRESS] EKG An EKG will be performed by [CONTACT_613042] 0 (the enrollment visit) and on Day 8 (Visit 3). EKG is indicated because both ciprofloxacin and fluconazole carry some risk of QTc interval prolongation. Prolonged QTc intervals are defined in section 3.4.2. Participants with a prolonged QTc interval at baseline will be excluded. Participants with a prolonged QTc interval on Day 8 will discontinue the fluconazole/ placebo aspect of the study medication regimen. The study coordinator will remove the fluconazole/ placebo from the blister pack to avoid accidental doses. [IP_ADDRESS] Laboratory Blood Evaluations Blood will be collected and processed by [CONTACT_32341]. The following testing will be performed: • ESR   ESR will be evaluated at the enrollment visit, day 8, day 15, and day 29.  • CRP  CRP will be evaluated at the enrollment visit, day 8, day 15, and day 29.  • CMP  CMP will be evaluated at the enrollment visit, day 8, day 15, and day 29.  • CBC without differential CBC without differential will be evaluated at the enrollment visit, day 8, day 15, and day 29. • Serum cystatin C   Serum cystatin C will be evaluated at the enrollment visit. Serum cystatin C, creatinine, BUN, and height will be used in the combined comprehensive eGFR equation to estimate eGFR in order to confirm eligibility.  • Vancomycin Level  Serum vancomycin levels will be tested on day 5 to monitor for systemic absorption of vancomycin. If the result is above the therapeutic range, vancomycin will be discontinued and serum vancomycin will be tested on day 8. If on day 8, serum vancomycin level is below the therapeutic range, vancomycin will be restarted, but the dose will be decreased by 25%. If the serum vancomycin level remains therapeutic or above therapeutic, vancomycin will not be restarted and the serum level will be rechecked on day 15.  
   
   23 • Drug levels for participants on biologics stored for future testing  At the enrollment visit, blood will be obtained for drug level and antibody testing for patients who are being treated with infliximab or adalimumab (ARUP laboratories). Serum will be stored frozen in ARUP transport tubes. Serum will be stored for future use so that it will be possible to correlate response to this regimen with biologic drug levels and presence or absence of biologic medication antibodies.    • Extra blood for storage for future testing Extra blood will be drawn and will be stored for future metabolomics studies at the enrollment visit, day 5, day 8, day 15, and day 29.  Total blood draws will not exceed 3ml/kg or 50 ml (whichever is greater) within an 8-week period. [IP_ADDRESS] Pregnancy Testing A urine pregnancy test will be performed for female subjects ³ 11 years of age and girls <11 years who are physically capable of becoming pregnant. [IP_ADDRESS] Stool Collection, Shippi[INVESTIGATOR_007], and Analysis Each participant will be provided with stool collection kits to take home during the course of the study. Participants will be instructed to collect a bowel movement at 5 time points – enrollment, Day 8, Day 15, Day 22, and Day 29. Stool samples will be returned to CHOP using pre-paid mailers, by [CONTACT_59274][INVESTIGATOR_613031] a satellite location, or by [CONTACT_613043] a study team member at a study visit. All specimens remaining after the study is complete will be retained for possible future use or it is deemed by [CONTACT_371125]. Stool sample from the enrollment will be sent to a CHOP lab for C. difficile testing (if not tested clinically within one month of enrollment).  Stool samples will be aliquoted for FCP testing and microbiome analyses. The remaining Stool will be stored in the laboratory of [CONTACT_309731] at the University of Pennsylvania. Microbiome analysis will occur through the PennCHOP Microbiome Center. At the enrollment visit, Study Visit 3, Study Visit 4, and Study Visit 6, participants will undergo a rectal swab for assessment of the mucosally-associated gut microbiota. Swabs will stored in a -80 freezer at the University of Pennsylvania.   All frozen swabs will be analyzed by [CONTACT_371128]. 
   
   24 5.1.2 Group 2 [IP_ADDRESS] Medical Record Review • Date of birth • MRN • Mailing address • Email address • Telephone number • Sex • IBD  history (including date of diagnosis, and disease location) • Prior use of medications • Current medications • Procedure reports and phone encounters associated with bowl prep  • Physical examination • Laboratory tests (including ESR, CRP, albumin, hematocrit, hemoglobin, fecal calprotectin, stool C. difficile toxin, drug levels for biologics) The above data elements will be abstracted manually from the electronic medical record by [CONTACT_464].  [IP_ADDRESS] Sample Collection  Stool samples will be collected at specified time points during the study, before and after undergoing PEG lavage. If participants are not seen in clinic during the study timeframe, specimen collection direction and supplies will be mailed to the participant. The family will use a stool collection hat to obtain the stool. Samples will be returned to CHOP. Samples will be processed for microbiome analysis identically to those of Group 1 participants.   5.2 Efficacy Evaluations 5.2.1 Diagnostic Tests, Scales, Measures, etc. The Pediatric Crohn’s Disease Activity Index is a validated, non-invasive scale that is widely used in clinical trials to assess Crohn’s disease activity among children [31].   The PCDAI scale incorporates self-reported symptoms, historical features, laboratory data (hematocrit, albumin, and ESR), and physical examination findings for an overall score of 0 to 100 [31].  The PCDAI includes the following measurements: 1. Subjective reporting of the degree of abdominal pain, stool pattern, and general well-being (recall over the past week). 2. Presence of extraintestinal manifestations, such as fever, arthritis, rash, and uveitis. 3. Physical examination findings. 4. Weight change and either height change or height velocity. 5. Hematocrit (HCT), erythrocyte sedimentation rate (ESR), and serum albumin.   A partial PCDAI score will be used to evaluate patients at enrollment. This will consist of the PCDAI score without the physical exam or laboratory component (HCT, ESR, and albumin) of the assessment. The subject reports the degree of abdominal pain, stools per day, and general well-being over the previous week. The scoring system is outlined in Table 3.The partial PCDAI is calculated as the sum of the scores from the 3 subjective questions in 
   
   25 the PUCAI, and ranges from 0 to 30. The partial PCDAI includes the following three measurements; scoring for each measurement is indicated in parentheses:  Table 3: Partial PCDAI Score Criteria   Symptom Degree Score  None  0 Abdominal Pain Mild: Brief, does not interfere with activities  5  Moderate/Severe: Daily, longer lasting, affects activities, nocturnal  10  0-1 liquid stools, no blood  0 Stools (per day) Up to 2 semi-formed with small blood, or 2-5 liquid 5  Gross bleeding, or >6 liquid, gross blood, or nocturnal diarrhea  10  No limitation of activities, well 0 Patient Functioning, General well-being Occasional difficulty in maintaining age-appropriate activities, below par 5  Frequent limitation of activity, very poor 10 Active disease will be defined as a PCDAI score >10 regardless of the FCP concentration [43].  To be defined as having achieved a full clinical response (remission), patients must have a PCDAI ≤10 or a 15 point reduction from week 0, and a FCP concentration ≤200 mcg/g. Group 1 participants with PCDAI≤10 or a 15 point reduction from week 0 but with elevated FCP (i.e. >200 mcg/g) will be considered partial responders.  The sCDAI, a modified score validated in adults that includes only the history elements[34], will be administered through the daily REDCap surveys on Day 1-29 and then weekly thereafter (see Section 4.3.1). The sCDAI is validated in the adult population, but there is no equivalent measure in the pediatric population. Therefore, the sCDAI will be used to evaluate disease activity in daily surveys.  Both PCDAI and sCDAI are validated measures of CD disease activity. The sCDAI is validated only in the adult population, but there is no equivalent measure in the pediatric population. Therefore, the sCDAI will be used to evaluate disease activity in daily surveys.   5.2.2 Fecal calprotectin Evidence suggests that fecal calprotectin (FCP) represents an excellent surrogate marker of intestinal inflammation and disease activity. Calprotectin is 36 kDa calcium- and zinc-binding protein that represents 60% of cytosolic proteins in granulocytes [35].  Furthermore, calprotectin is highly stable in feces when stored at room temperature for up to 1 week [6].  Clinically, the concentration of calprotectin in feces (FCP) is used as a non-invasive measure of neutrophilic infiltrate in the bowel mucosa, and thus intestinal inflammation. The correlation of decreased FCP concentration to mucosal healing has been demonstrated by [CONTACT_371129]’s disease [7]. This has been confirmed in both adult and pediatric populations with Crohn’s disease [8, 9]. A recent meta-analysis identified a cut point of 250 mcg/g as optimal to distinguish the presence or absence of endoscopi[INVESTIGATOR_371071] [41]. However, reduction in FCP is also used to assess 
   
   26 improvement. For example, following treatment with anti-TNF therapy, FCP has been demonstrated to dramatically decline [42].    In this study, FCP concentration will be assessed using ELISA methods. The results of each stool calprotectin will be entered into CHOP’s electronic medical record and shared with the participant’s primary gastroenterologist.  Stool calprotectin is used as a marker of intestinal inflammation.  It is standard-of-care at the CHOP Inflammatory Bowel Center to consider any stool calprotectin value above 250µg/g as significantly elevated.   5.2.3 C-reactive protein (CRP) C-reactive protein is produced mainly in hepatocytes in response to acute phase stimuli such as inflammation.  Its production is driven by [CONTACT_371130]. C-reactive protein is commonly used to screen the activity of chronic inflammatory diseases including IBD. In general, patients with CD have a high CRP when the disease is active and a normal CRP when the disease is quiescent.  CRP will be tested through a CHOP laboratory. 5.2.4 Microbial DNA sequencing DNA will be prepared in the PennCHOP Microbiome Center. Samples will be sent to the center de-identified and coded with a study number. We will perform 16S rRNA and ITS gene sequencing to evaluate the bacterial and fungal microbiota, respectively, in stool and rectal swab samples. Isolated DNA will be quantified using the Pi[INVESTIGATOR_309688] 50 ng of DNA will be amplified.  Pyrosequencing will be carried out using barcoded primers as previously described [10].  For pyrosequencing of bacteria, primers annealing to the V1V2 region of the 16S bacterial gene will be used.  The development of the ITS1 fungal primers is described in [10].  For pyrosequencing, we will use the [COMPANY_002]/454 Genome Sequencer Junior.  Sequence data will be processed using QIIME [11]. If warranted by [CONTACT_613044], samples may be analyzed further using a metagenomic approach, in which DNA samples are nebulized, ligated to linkers, and subjected to pyrosequencing (IlluminaHiSeq).  This allows enumeration of the types of genes present in a sample. To determine bacterial and fungal load, respectively, we will determine 16S and 18S gene copy number from the stool and rectal swab samples. The qPCR methods including the details of the primers as well as PCR cycling conditions have been previously described [12]. 5.3 Safety Evaluation Participant safety will be monitored by [CONTACT_12902], medication side effects, vital signs, physical examinations, and laboratory data. The Principal Investigator [INVESTIGATOR_371072], nausea/vomiting, increased abdominal pain, and increased diarrhea from baseline (see Section 8).  Adverse events will be compared to all known side effects of the antimicrobials prescribed through the current study (see Section 9.5.2). All adverse events will be tracked and assessed by [CONTACT_978]. Adverse events will be reported according to CHOP Research Policy and Procedure – please see Section 9.5.1 for additional safety monitoring details for this study. 
   
   27 6 STATISTICAL CONSIDERATIONS 6.1 Primary Endpoint The primary endpoint will be the change in disease activity, as measured by [CONTACT_613045], between the enrollment visit and Day 15 for Group 1 participants. All participants who withdraw for any reason prior to day 15 will be considered treatment failures.  To be defined as having achieved a full clinical response (remission), patients must have: • A PCDAI ≤10 or a 15-point reduction from week 0, and a FCP concentration ≤200 mcg/g.  • Participants with PCDAI≤10 or a 15-point reduction from enrollment but with elevated FCP (i.e. > 200 mcg/g) will be considered partial responders. 6.2 Secondary Endpoints Secondary endpoints will include the following: • The change in CRP between the enrollment visit and Day 15 • Correlation of effectiveness in reducing bacterial 16S and fungal 18S rRNA copy number, by [CONTACT_371099], with improvement of disease activity in patients with CD or IBDU that is refractory to immunosupression. • The relationship between the effectiveness of the proposed regimen with changes to the composition of the gut microbiota • Safety and tolerability of the treatment regimen based on medication side effects and/or adverse events (AEs). • The change in FCP between baseline, Day [ADDRESS_812679] descriptive statistics. Categorical variables will be compared using Fisher’s exact test and continuous variables will be compared using the unpaired t-test or Wilcoxon rank sum test if the data are not normally distributed.   Our estimates of efficacy will use four outcome measures: clinical response, clinical remission, reduction in FCP concentration, and reduction in CRP. For clinical response (reduction of score on PCDAI by 15 or more points) we will report the proportion and binomial 95% confidence intervals. Similar methods will be used for remission (PCDAI <10). Although 250 mcg/g has been recently recommended, there is no standard definition of a clinically meaningful reduction in FCP and many definitions have been used. Therefore, we will use a paired t-test (after applying a log transformation if necessary) to establish 
   
   28 whether the FCP concentration is lower following therapy than at baseline and we will also report the proportion of patients with reduction in FCP to less than 250 mcg/g among the subset with baseline FCP > 350 mcg/g.  Similarly, there is no standard definition of a clinically meaningful reduction in CRP.  Therefore, we will use a paired t-test (after applying a log transformation if necessary) to establish whether the CRP is lower following therapy than at baseline. As a Phase 2a study to determine the effectiveness of the two treatment arms to induce a clinical response or remission, with 20 participants, it is possible to generate the required data [44].   We are not examining efficacy in Group 2. The primary outcome is reduction in FCP with PEG lavage. We will use a paired t-test (after applying a log transformation if necessary) to establish whether the FCP concentration is lower following PEG lavage than at baseline. From our preliminary data and the expected mean and standard deviation of the paired differences, 15 patients will allow us to achieve 80% power and a level of significance of 5%.  To detect reduction in bacterial and fungal load by 16S and 18S gene copy number we will use a paired t-test after applying a log transformation. Based on the preliminary data, it is assumed that the standard deviation of change will be approximately 0.[ADDRESS_812680] 90% power, this requires only [ADDRESS_812681] deviation is greater, say 1 or 2 log, the required sample size is 5 or 13, respectively.  We will measure the Pearson’s correlation to determine the relationship between copy numbers and the outcome measures listed above (PCDAI, FCP, and CRP). If all patients do not have >2 log drop in 16S and 18S copy number, we will compare clinical remission and response among those with and without >2 log drop using Fisher’s exact test.  The main statistical and computational tool for comparing the bacterial gut microbiota among different groups (e.g. between samples from different time points) is the phylogenetic-based method as implemented in the program UniFrac [47, 48], which measures the similarity among the community based on phylogenetic distances determined by [CONTACT_941] 16S rRNA gene sequences of different bacteria. Based on these distances, we can cluster the microbiomes using the Principal Coordinate Analysis (PCoA) along axes of maximal variance.  The significant principal components can then be compared between two groups using the two sample t-tests. Permutations can be used to obtain the p-values. Alternatively, we can compare several principal components simultaneously by [CONTACT_371134]. Specifically, we can randomize the labels of the groups and compare all distances between points that both come from the same group to all distances between points from different groups using t-tests. In such permutation test, we can obtain a nonparametric distribution of the t statistic that takes into account the correlations introduced by [CONTACT_371135]-wise distance matrix structures. For the fungal community distances, Jaccard and abundance-weighted Jaccard indices will be calculated. 
   
   29 6.3.1 Safety Analysis All subjects enrolled into the study will be included in the safety analysis. The frequencies of AEs by [CONTACT_24975], severity and relationship to study drug will be summarized. SAEs (if any) will be described in detail. AE incidence will be summarized along with the corresponding exact binomial 95% two-sided confidence intervals. We expect that adverse events will occur because the participants included in this study will have active, refractory disease.  Thus, hospi[INVESTIGATOR_371073]-threatening events may occur.  However, we anticipate very few, if any, adverse events that are directly related to the proposed intervention. 
   
   30 7 STUDY MEDICATION  7.1 Intervention Description and Regimen Only Group 1 participants will be administered the study drug regimen. The antimicrobial regimen will include 3 days of vancomycin and neomycin followed by 11 days of vancomycin and ciprofloxacin. Group 1 participants will also be randomized in a double-blinded fashion to fluconazole or placebo for 14 days.  Drug Dosage Form Dosage Regimen Vancomycin 500 mg/ 20 mL oral suspension 40 mg/kg/day in [ADDRESS_812682] 50mg; not to exceed 500 mg PO every 6 hours Days 1-14 Neomycin 500 mg tablet 10-20 kg: 250 mg PO every 8 hours 20-40 kg: 500 mg PO every 8 hours >40 kg: 1000 mg PO every 8 hours  Day 1-3 Ciprofloxacin 250 mg tablet, 500 mg tablet, 750 mg tablet  10-12.5 kg: 125 mg PO twice per day 12.5-22.5 kg: 250 mg PO twice per day 22.5-27.5 kg: 375 mg PO twice per day 27.5-37.5 kg: 500 mg PO twice per day 27.5-40 kg: 625 mg PO twice per day >40 kg:750 mg PO twice per day Days 4-14 Encapsulated fluconazole or placebo capsule 50 mg capsule, 100 mg capsule 10-20 kg: 50 mg PO in one dose daily  20-25 kg: 100 mg PO in one dose daily 25-30 kg: 150 mg PO in one dose daily 30-40 kg: 200 mg PO in one dose daily 40-50 kg: 250 mg PO in one dose daily 50-60 kg: 300 mg PO in one dose daily >60 kg: 400 mg PO in one dose daily  Days 1-14 
Miralax (PEG 3350) Powder (dissolved in Gatorade or Crystal Lite) 10-13 kg: 51 g dissolved in 24 oz 14-17 kg: 68 g dissolved in 32 oz 18-22 kg: 85 g dissolved in 40 oz 23-26 kg: 102 g dissolved in 48 oz 27-30 kg: 119 g dissolved in 56 oz 31-34 kg: 136 g dissolved in 64 oz 35-40 kg: 153 g dissolved in 64 oz 41-42 kg: 170 g dissolved in 64 oz 43-46 kg: 187 g dissolved in 64 oz 47-50 kg: 204 g dissolved in 64 oz >50 kg: 238 g dissolved in 64 oz Day 2  
   
   31 7.1.1 Dispensing The University of Pennsylvania’s Investigational Drug Service (IDS) will prepare and dispense the drugs for this study. 7.1.2 Receipt After confirmation of eligibility, participants will be sent the antimicrobial and lavage regimen listed above directly from Penn IDS to their home mailing address. Participants and their parent/guardian will be provided with a checklist of all study medications and will be instructed to report any discrepancies to a member of the study team. 7.1.3 Storage Study medications will be prepared, stored, and dispensed by [CONTACT_613046]. 7.1.4 Preparation and Packaging To promote participant compliance and minimize potential confusion, study medications will be packaged into 2 blister packs: one for Days 1-7 and the other Days 8-14. The rows of the blister packs will be labeled clearly, with each dose separated into blisters. The vancomycin suspensions will be packaged in separate Ziploc bags per day.  Each bag will contain four syringes containing the appropriate dosage of vancomycin. The Day 2 bag will additionally contain a bottle with PEG 3350.  At the enrollment visit, participants will be provided with a 64 ounce water pi[INVESTIGATOR_613032] 2 32 ounce bottles of Gatorade.  With the exception of vancomycin and fluconazole, all study medications will be distributed in their original formulation as per the manufacturer. For vancomycin, IDS will compound the prescribed total dosage for the oral suspension (500 mg/20 mL concentration) drawn up into individual syringes based on dosage. For fluconazole, IDS will encapsulate the original formulation tablets so that they will look identical to placebo capsules. 7.1.5 Administration and Accountability Participants will be provided with all study medications by [CONTACT_613047].  Participants will take all medications orally. All unused study medications and empty containers will be collected from each participant and/or their parent/guardian at the completion of their participation.   7.1.6 Participant Compliance Monitoring Compliance will be monitored through study staff observation of empty blister packs and/or syringes at each in person visit (see Section 7.1.7). At each in-person visit, participants and/or their parent/guardian will be asked to bring in their used and unused blister packs, syringes, and PEG bottle for review by [CONTACT_464].  Compliance will be reviewed with the participants and/or their parent/guardian throughout the study. 
   
   [ADDRESS_812683] be returned to the study team. 8 SAFETY MANAGEMENT 8.1 Clinical Adverse Events Clinical adverse events (AEs) will be monitored throughout the study.  8.2 Adverse Event Reporting Unanticipated problems related to the research involving risks to subjects or others that occur during the course of this study (including SAEs) will be reported to the IRB in accordance with CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. AEs that are not serious but that are notable and could involve risks to subjects will be summarized in narrative or other format and submitted to the IRB at the time of continuing review.  8.[ADDRESS_812684] who has received an intervention (drug, biologic, or other intervention).  The occurrence does not necessarily have to have a causal relationship with the treatment.  An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs (including serious AEs) will be noted in the study records and on the case report form with a full description including the nature, date and time of onset, determination of non-serious versus serious, intensity (mild, moderate, severe), duration, causality, and outcome of the event. 8.4 Definition of a Serious Adverse Event (SAE) An SAE is any adverse drug experience occurring at any dose that results in any of the following outcomes:  • death, • a life-threatening event (at risk of death at the time of the event),  • requires inpatient hospi[INVESTIGATOR_1081], • a persistent or significant disability/incapacity, or 
   
   33 • a congenital anomaly/birth defect in the offspring of a subject.   Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse drug event when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. 8.4.1 Relationship of SAE to study drug or other intervention The relationship of each SAE to the study intervention should be characterized using one of the following terms in accordance with CHOP IRB Guidelines: definitely, probably, possibly, unlikely or unrelated.  8.5 IRB/IEC Notification of SAEs and Other Unanticipated Problems The Investigator will promptly notify the IRB of all on-site unanticipated, serious Adverse Events that are related to the research activity. Other unanticipated problems related to the research involving risk to subjects or others will also be reported promptly. Written reports will be filed using the eIRB system and in accordance with the timeline below.  Type of Unanticipated Problem Initial Notification  (Phone, Email, Fax) Written Report Internal (on-site) SAEs Death or Life Threatening  24 hours Within 2 calendar days Internal (on-site) SAEs All other SAEs 7 days Within 7 business days Unanticipated Problems Related to Research 7 days  Within 7 business days All other AEs N/A Brief Summary of important AEs may be reported at time of continuing review 8.5.1 Follow-up report If an SAE has not resolved at the time of the initial report and new information arises that changes the investigator’s assessment of the event, a follow-up report including all relevant new or reassessed information (e.g., concomitant medication, medical history) will be submitted to the IRB. The investigator is responsible for ensuring that all SAE are followed until either resolved or stable.  8.[ADDRESS_812685] hospi[INVESTIGATOR_613033].  One such medical emergency that may occur is a severe allergic reaction to a study medication. 
   
   34 9 STUDY ADMINISTRATION 9.1 Treatment Assignment Methods 9.1.1 Randomization Stratified randomization to fluconazole versus placebo will be performed using a 1:1 ratio of treatment arms. The randomization order will be created by [CONTACT_323259]’s Investigational Drug Service (IDS). 9.1.2 Blinding The randomization schedule will be generated by [CONTACT_371109]. Neither the participant, the study team, nor the clinical site personnel will know the treatment group to which any participant is randomized. 9.1.3 Unblinding If there is a serious adverse event, which is thought by [CONTACT_371110], the principal investigator, when necessary for the safety of the participant, will unblind treatment group assignment.  The following procedures will be taken when the principal investigator [INVESTIGATOR_371066]: The IDS will be notified by [CONTACT_371111].  IDS will unblind the treatment group assignment and provide it to the study team. Unblinding of treatment assignment is anticipated to be an uncommon occurrence and is highly discouraged.  Unblinding should only be performed if deemed necessary for the safety of the participant.   9.2 Data Collection and Management • In order to ensure confidentiality, all subjects will be given a study ID number that will used to identify them on all data collection documents. Data will also be recorded on a shared REDCap account, an online database shared amongst the study team members at CHOP and Penn. All information collected in this study will be kept confidential as required by [CONTACT_2371].  • An enrollment log linking PHI to study ID number will be kept on a password protected excel document on the CHOP Research Secure Server (SAND). Only study personnel at the CHOP site will have access to the enrollment log. The study team will be responsible for data collection, data management and accurate record keepi[INVESTIGATOR_007]. Upon completion of all study procedures and analyses, the enrollment log, linking PHI to subject study IDs will be destroyed when deemed no longer necessary.   • The study team will oversee appropriate collection, storage and shippi[INVESTIGATOR_26172]. For stool samples collected during post discharge follow ups, subjects will be asked to either bring samples to CHOP or ship the samples to the laboratory using provided pre-paid shippers. Samples will be processed and stored in a -80°C freezer. Subject will be instructed to properly label the samples with the date of collection, study ID 
   
   [ADDRESS_812686] access to this information: the research team, Penn IDS, medical staff who are directly or indirectly involved in patients’ care, and the CHOP IRB.  9.4 Records Retention Study documents and data will be retained in accordance with CHOP’s retention policy. 9.5 Regulatory and Ethical Considerations 9.5.1 Data and Safety Monitoring Plan An Investigational New Drug (IND) Exemption has been obtained from the University of Pennsylvania IND/IDE Support Unit within the Penn Office of Clinical Research. As part of an established safety and monitoring plan, the Primary Investigator will monitor adverse events and unanticipated problems during the study to monitor ongoing participant safety. A Safety Officer, Natalie Terry, MD, PhD, has been identified to provide additional monitoring for the study. This individual is a board-certified gastroenterologist in pediatric practice who is knowledgeable in the natural history and treatment of CD, but who is not directly involved in the study and has no conflict of interest, financial or otherwise.  Following CHOP IRB guidelines, all onsite, unanticipated SAEs will be reported to the Safety Officer promptly (within 24 hours) in the form of a written narrative. This will include a copy of the completed Serious Adverse Event form and any other information that will assist the understanding of the event. Significant new information for ongoing serious adverse events should be provided promptly to the study sponsor. All other adverse events will be reported to the Safety Officer quarterly. Based on these reports, the Safety Officer will have the authority to suspend the study and to convene a Data and Safety Monitoring Board (DSMB) as necessary. We do not feel that a DSMB is necessary at the time of study launch given the open-label design and utilization of FDA-approved medications. This monitoring plan, in addition to screening for prolonged QTc and kidney and liver dysfunction, has been established to ensure the safety of the investigational regimen in this population.  During the trial, study medications will be paused in the event of a serious adverse event that qualifies as a CTCAE Grade [ADDRESS_812687] of care under the guidance of their treating physician. His/her data will still be used in the final analyses.  9.5.2 Risk Assessment [IP_ADDRESS] Group 1 Participation There are potential risks to participants who agree to participate in this trial; however, the risks are relatively small and have been minimized by [CONTACT_91939]. Group [ADDRESS_812688] one conventional therapy. Many of these patients will otherwise be facing escalation of therapy to a medication that is considered experimental or will be facing surgery. The risks associated with this study are significantly less than the risks associated with surgery. The risks of each medication will be reviewed in detail as part of the consent process.   As the participants’ concurrent therapi[INVESTIGATOR_371076], the probability of harm is very low. Participants can be withdrawn from the study at any time. Additionally, if a participants’ condition worsens and a rescue therapy is deemed necessary by [CONTACT_371139], the participant will be withdrawn. Risks Associated with Study Medications The therapeutic regimen described in this protocol is safe. These are medications that are already FDA approved for various indications. The protocol is using standard dosing. Also, many of the medications in the proposed regimen are already utilized in children and adults with CD. In the preliminary data, it was found a similar regimen to be safe in primates. No SAEs related to the drug regimen have been reported for the five subjects enrolled in the IRB-approved protocol being conducted through Penn. Subjects with a known allergy to any of the study medications will not be able to participate. Subjects who do not know how they will react to the study medications are at risk for an allergic reaction including anaphylaxis. Anaphylaxis is a severe, potentially life-threatening allergic reaction. It can occur within seconds or minutes of exposure to something someone is allergic to. The flood of chemicals released by [CONTACT_613048], making it hard to breathe normally. Signs and symptoms of anaphylaxis include a rapid, weak pulse, a skin rash, nausea and vomiting. Anaphylaxis requires immediate medical attention including an injection of epi[INVESTIGATOR_238]. If anaphylaxis is not treated right away, it can lead to unconsciousness or even death.  For any antibiotic, there is the possibility of “resistance” developi[INVESTIGATOR_007]. Resistance means that specific, infection-causing bacteria that were treatable by [CONTACT_613049]. 
   
   37 For any antibiotic, there is also the possibility that subjects could develop Clostridium difficile. However, vancomycin, one of the study medications, is used to treat C. difficile and therefore, the chances of developi[INVESTIGATOR_007] C. difficile while on study medications is extremely unlikely.  Known Adverse Reactions to Study Medications Ciprofloxacin (Cipro) Reactions found in Clinical Trials in Pediatric Populations Common Reactions (occurs in > 5% of patients) • Temporary mild to moderate negative musculoskeletal reactions: o Joint pain o Joint sprains  o Decreased range of joints  o Degeneration of joints  o Abnormal walking patterns o Body and muscle pain Less Common Reactions (occurs in 1-5% of patients) • Diarrhea • Vomiting • Abdominal pain  • Stuffy nose • Indigestion • Nausea • Fever • Asthma • Rash  • Dizziness • Nervousness • Trouble sleepi[INVESTIGATOR_007] • Drowsiness • Laboratory value changes Reactions found in Clinical Trials in Adult Populations (possible in pediatric populations) Common Reactions (occurs in 1-2.5% of patients) • Nausea • Diarrhea • Abnormal liver function tests • Vomiting • Rash Rare but Potentially Dangerous Reactions (occurs in <1% of patients) 
   
   38 • Body related pain (i.e. headaches, abdominal pain, foot pain, etc.)  • Blood flow (i.e. abnormal heart beat, high/ low blood pressure, heart attack, minor bleeds in the skin, swollen lymph nodes etc.)  • Mental state (i.e. restlessness, dizziness, trouble sleepi[INVESTIGATOR_007], drowsiness, irritability, hallucinations, depression, poor appetite, etc.)  • Gastrointestinal system (i.e. difficulty swallowing, intestinal perforation, GI bleeding, jaundice, hepatitis, etc.)  • Metabolism and nutritional systems (i.e. increase in pancreas labs, high or low blood sugar) • Musculoskeletal system (i.e. joint, back, neck or chest pain, joint stiffness, achiness, gout flare up)   • Kidneys, urinary or genital organs (i.e. kidney inflammation, kidney failure, bloody urine, breast pain, vaginal pain, discharge or itching, etc.)  • Breathing (i.e. shortness of breath, nose bleeds, fluid in the lungs, inflamed larynx, hiccup, coughing up of blood, blood clot in lungs etc.)  • Skin and sensitivity (i.e. allergic reaction, fever, chills, sweating, itchy skin, sensitivity to the sun, flushing, swelling of the face, neck, lips etc.)  • Senses (i.e. blurred vision, change in color perception, vision loss, double vision, hearing loss, bad taste etc.)   Vancomycin Reactions found in Clinical Trials in Adult Populations (possible in pediatric populations) Common Reactions (occurring in > 5% of patients) • Nausea • Abdominal pain • Vomiting • Diarrhea • Gassiness • Decreased potassium levels • Fever  • Swelling of feet, ankles, or legs • Fatigue • Urinary tract infection • Back pain • Headache • Kidney failure • Increased kidney laboratory values Additional possible reactions. The likelihood of having these side effects is unknown. • Toxicity to the ear: (i.e. hearing loss (associated with IV therapy), vertigo, dizziness, hearing extraneous sounds i.e. ringing, clicking etc.) • Blood cells: (i.e. reversible low white blood cell count)   • Miscellaneous (i.e. anaphylaxis, chills, rash, life-threatening skin condition, blood vessel destruction by [CONTACT_2898]) 
   
   39  Neomycin Reactions reported during treatment with Neomycin Common Reactions • Nausea • Diarrhea • Vomiting Other Adverse Reactions • Brain system: (i.e. nerve damage, damage to the inner ear (which could lead to temporary or permanent hearing loss and balance),  paralysis of the nerve and muscle systems, which may cause death, severe difficulty breathing, numbness, skin tingling, muscle twitching and convulsions)  • Kidney: (i.e. damage to kidney, kidney failure) • Neonatal: (i.e. harm to an unborn baby [CONTACT_613050] a pregnant woman,  permanent hearing loss at the time of birth)  • Miscellaneous: (i.e. yeast infection and other similar infections, inability to absorb certain nutrients, leading to increased fat, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin and iron in the stool)  Fluconazole Reactions found in Clinical Trials in Pediatric Populations Common Reactions (occurs in 1-5% of patients) • Vomiting  • Abdominal Pain  • Nausea  • Diarrhea  • Abnormal liver function tests Reactions found in Clinical Trials in Adult Populations (possible in pediatric populations) Common Reactions (occurs in 1-5% of patients) • Headache • Nausea  • Skin rash  • Abdominal pain  • Vomiting  • Diarrhea  • Dyspepsia  • Dizziness • Taste perversion • Abnormal liver function tests Rare but Potentially Dangerous Reactions  
   
   40 • Liver: (i.e. gallbladder inflammation, yellowing of the skin, liver damage, serious liver infections like hepatitis, sudden liver failure which could lead to death in those with serious underlying medical conditions) • Miscellaneous (i.e. anaphylaxis, rapid swelling of the skin, birth defects when taken during early pregnancy)  Other Post-Marketing Adverse Reactions • Heart  (i.e. irregular heart rhythms, abnormal heart rhythm disorders)  • Blood cells (i.e. decreased white blood cells and platelets)  • Body (i.e. abnormal weakness, lack of energy, tiredness, discomfort or uneasiness, fever)  • Brain (i.e. seizures, dizziness, sleepi[INVESTIGATOR_332805], sleepi[INVESTIGATOR_008], tremor, vertigo, nerve damage- characterized by [CONTACT_158488], tickling, prickling, burning etc. of the skin without a physical cause) • Skin (i.e. rash caused by [CONTACT_613051], life-threatening skin conditions, increased sweating, hair loss)  • Metabolism and nutritional system (i.e. increased blood cholesterol, increased blood triglycerides, low blood potassium)  • Gastrointestinal (i.e. blockage of bile to the duodenum, dry mouth, indigestion, vomiting, changes in taste)  • Miscellaneous (i.e. anaphylaxis, rapid swelling of the skin, swelling of the face, severe itching of the skin, liver damage, muscle pain)   MiraLax (PEG 3350) Reactions reported during treatment with MiraLax (PEG 3350) Common Reactions • Nausea • Abdominal Bloating • Crampi[INVESTIGATOR_007] • Flatulence • Diarrhea and excessive stool frequency with high doses • Hives   Reproductive Risks It is unknown what effect these treatments may have on an unborn child. Subjects of childbearing age will be asked to practice an effective method of birth control while participating in this study. Potential subjects will be made aware that taking oral antibiotics can potentially lower the effectiveness of oral birth control. If a subject becomes pregnant 
   
   [ADDRESS_812689] methods will be used to prevent infection.  Stool Collection Any stool sample may contain germs that spread disease. Subjects will be asked to carefully wash their hands and use careful handling techniques to avoid spreading infection. Subjects will be provided with directions on how to properly and safely package and ship samples (if applicable). Rectal Swab Collection Subjects may experience minor physical discomfort while having the swabs taken. EKG Subjects may experience minor physical discomfort or anxiety while having the EKG procedure. [IP_ADDRESS] Group [ADDRESS_812690] is comfortable with the process.  Breach of Confidentiality As with any study involving collection of data, there is the possibility of breach of confidentiality of data. Every precaution will be taken to secure participants' personal information to ensure confidentiality. At the time of participation, each participant will be assigned a study identification number. This number will be used on data collection forms and samples and in the database instead of names and other private information. 
   
   42 9.5.3 Potential Benefits of Trial Participation [IP_ADDRESS] Potential Benefits to Group [ADDRESS_812691] benefit is improvement in disease activity and potential salvaged response to the prior treatment regimen (immunomodulator or biologic medication). In terms of indirect benefits, participation in this study will improve the understanding of the role of the gut microbiota in the inflammatory bowel diseases. Finally, the new knowledge about the gut microbiota that stands to be gained presents an additional benefit of this study, further contributing to the favorable balance of potential benefits to possible harms. [IP_ADDRESS] Potential Benefits to Group [ADDRESS_812692] of bowel lavage on the gut microbiota and the gut inflammatory marker, fecal calprotectin.  9.5.4 Risk-Benefit Assessment [IP_ADDRESS] Group 1 The potential benefits outweigh any risks of participating in this study, as the treatment may help to salvage response to prior treatment regimens. The risks of participating in this study are small, and these risks are outweighed by [CONTACT_613052] a role in inflammatory bowel disease management.  [IP_ADDRESS] Group [ADDRESS_812693]. Christopher’s Hospi[INVESTIGATOR_613034] I. duPont Hospi[INVESTIGATOR_7722], to request referrals and help propagate information about the study to potential subjects. Potential subjects may be provided with the study team’s contact [CONTACT_613053]. Non-CHOP physicians may also obtain permission from potential subjects to release limited contract information to the study team so they may contact [CONTACT_613054]. Additionally, families may be approached at CHOP sponsored education meetings and events. Appropriate follow up from the study team may occur by [CONTACT_61529]. Contact [CONTACT_613055] a link to www.clinicaltrials.gov for more information. 
   
   43 An IRB approved flyer may also be distributed to potential participants. This document is attached in section 12.02 (1.0) of the IRB application. Flyers may be mailed, emailed, or handed out in-person. We also may be contact[CONTACT_613056], such as www.clinicaltrials.gov, the Crohn’s and Colitis Foundation of America (CCFA) Clinical Trial Registry, and the CHOP Clinical Research Finder public website by [CONTACT_613057]. Web-based advertising avenues, like eNewsletters, may be utilized in recruitment efforts including targeted advertising through local disease/health foundations such as the Crohn’s and Colitis Foundation of America (CCFA).  We will conduct a social media campaign via the CCFA Facebook page. The Facebook posts will guide potential participants to contact [EMAIL_11644] to receive more information about the study. The study’s posts will be managed by [CONTACT_613058], who have their own team of experts to monitor posts/comments.  There may be additional social media recruitment campaigns through the CHOP recruitment enhancement core or though the University of Pennsylvania. All materials and language posted will obtain IRB approval. If there are questions regarding initial eligibility, necessary information from the participant’s medical record will be obtained by [CONTACT_177705]/or a member of the study team. 9.6.[ADDRESS_812694] via email will be done with IRB approved language. Appropriate follow up from the study team may occur by [CONTACT_61529]. If there are questions regarding initial eligibility, necessary information from the participant’s medical record will be obtained by [CONTACT_177705]/or a member of the study team.  9.7 Informed Consent/Assent and HIPAA Authorization Study personnel will obtain consent and assent for the study. Subjects may make a decision about study participation at that time, or may decide to enroll at a later visit.  The study will be thoroughly explained by [CONTACT_3462], including the study rationale and goals.  For participants enrolled in Group 1, a physician on the study will explain the risks and benefits of the intervention and study procedures that are greater than minimal risk. A physician or another member of the research team, with consenting authority, will explain the rest of the consent form. Potential participants will be given the opportunity to ask questions to the physician and other study personnel about the study, risks, benefits, and confidentiality. Written consent will be obtained after all the questions and discussions have been completed. If a physician on the research study has not personally completed the consent form, signed and dated it himself/herself, a note will be included in either the 
   
   [ADDRESS_812695] indicating that the consent conversation occurred. For the subjects under 18 years of age, assent will be obtained by [CONTACT_613059]/guardian is present. Participation in all areas of the study will be completely voluntary. Should the subjects become intolerant of any aspect of the study, their participation will be discontinued. Subjects who turn 18 during the course of the study will be re-consented. For participants recruited through the outpatient clinic, written consent will be obtained at that outpatient visit, a REDCap Screening Questionnaire will be completed, and participants will be scheduled for an enrollment CTRC visit.  [IP_ADDRESS] Verbal Consent & Waiver of Documentation of Consent  We are requesting to obtain verbal consent and waiver of documentation of consent for participants enrolled in both Group 1 and Group 2 of the study.  [IP_ADDRESS].1 Group 1 For participants recruited through physician referrals or for potential subjects who are not at CHOP prior to enrollment, they may be contact[CONTACT_613060]. Once verbal consent is obtained, potential participants or their parent/guardian will be emailed a REDCap Screening Questionnaire. Participants who seem to meet all inclusion criteria (see Section 3.4) will be scheduled for an enrollment visit. The purpose of the verbal screening informed consent is to confirm the participant’s eligibility and obtain an IBD history. It is also to allow subjects to collect samples at home prior to their visit. Subjects are not always able to have a bowel movement while at the hospi[INVESTIGATOR_613035], it will be helpful for subjects to collect the stool sample at home prior to their appointment. A stool collection kit will be given to or mailed to all participants and/or their parent/guardian so that a sample can be brought to the enrollment visit. When consent is obtained by [CONTACT_756], the person obtaining consent will document the participant’s agreement to participate on the verbal consent form. We could not practicably carry out the research without the verbal consent, because it is possible that not all subjects will be seen at the main hospi[INVESTIGATOR_613036]. At the enrollment visit, the study will be reviewed in its entirety with the participant and the participant’s parents/guardian. Written consent and assent will be obtained. No samples will analyzed before obtaining written consent. [IP_ADDRESS].[ADDRESS_812696] will be given the opportunity to receive a copy of the consent. For subjects being consented via the telephone the following sections on waiver of assent, and waiver of HIPAA authorization apply.  [IP_ADDRESS] Waiver of Assent A full waiver of assent is requested for the verbal consent forms (Verbal Screening Informed Consent Form; to be used with Group 1 participants only and the Verbal Informed Consent Form; to be used with Group 2 participants only) which can be done over the telephone with parents/guardian and children may not be available. [IP_ADDRESS].1 Group 1 At the enrollment visit, the study will be reviewed in its entirety with the participant and the participant’s parents/guardian. Written assent will be obtained at this in-person visit and documented on the main consent form All Group 1 participants and/or their parent/guardian must provide written consent before undergoing any other study procedures. The study procedures will be explained to each participant and their parent/guardian at the time of pre-screening and written consent. If the participant agrees to further participate, the written informed consent form will be signed in-person at either the outpatient clinic visit or the enrollment visit.  [IP_ADDRESS] Waiver of HIPPAA Authorization A partial waiver of HIPAA authorization to obtain verbal authorization is requested for both Group [ADDRESS_812697] samples prior to being seen at CHOP or for subjects who will not require a visit to CHOP.   9.8 Payment to Subjects/Families All participants will be provided compensation for their enrollment in this study. Participants will be compensated $10.[ADDRESS_812698]. If all sample collections are completed an addition $70 will be provided. Group 1 participants can earn a maximum of $120 for their participation in the study. Group 2 participants can earn a maximum of $[ADDRESS_812699] access to any medical information.  9.8.1 Gifts Group 1 participants will be given a pi[INVESTIGATOR_613037] (PEG 3350) solution for the day 2 bowel lavage. 
   
   46 10 PUBLICATION Data from this study, including preliminary data analyses, will be presented at national meetings and submitted for publication.  Confidentiality will be maintained during publication.   11 REFERENCES 1. Lewis, J.D., The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology, 2011. 140(6): p. 1817-1826 e2. 2. Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54 e42; quiz e30. 3. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol, 2006. 3(7): p. 390-407. 4. Rath, H.C., et al., Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun, 2001. 69(4): p. 2277-85. 5. Elson, C.O., et al., Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann N Y Acad Sci, 1998. 859: p. 85-95. 6. Harper, P.H., et al., Role of the faecal stream in the maintenance of Crohn's colitis. Gut, 1985. 26(3): p. 279-84. 7. Rutgeerts, P., et al., Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet, 1991. 338(8770): p. 771-4. 8. Dave, M., et al., Opportunistic Infections Due to Inflammatory Bowel Disease Therapy. Inflamm Bowel Dis, 2013. 9. Ben-Horin, S. and Y. Chowers, Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther, 2011. 33(9): p. 987-95. 10. Hoentjen, F., et al., Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut, 2003. 52(12): p. 1721-7. 11. Kang, S.S., et al., An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med, 2008. 5(3): p. e41. 12. Madsen, K.L., et al., Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology, 2000. 118(6): p. 1094-105. 13. Khan, K.J., et al., Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol, 2011. 106(4): p. 661-73. 14. Wang, S.L., Z.R. Wang, and C.Q. Yang, Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med, 2012. 4(6): p. 1051-1056. 15. Ohkusa, T., et al., Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol, 2010. 105(8): p. 1820-9. 16. Uehara, T., et al., Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. J Gastroenterol Hepatol, 2010. [ADDRESS_812700] 1: p. S62-6. 17. Terao, S., et al., Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion, 2011. 83(3): p. 198-203. 
   
   47 18. Turner, D., et al., Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report. J Crohns Colitis, 2014. 19. Iliev, I.D., et al., Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science, 2012. 336(6086): p. 1314-7. 20. Barclay, G.R., et al., The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol, 1992. 27(3): p. 196-200. 21. Zwolinska-Wcislo, M., et al., Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol, 2009. 60(1): p. 107-18. 22. Dollive, S., et al., Fungi of the Murine Gut: Epi[INVESTIGATOR_371077]. PLoS One, 2013. 8(8): p. e71806. 23. Wellmann, W. and F.W. Schmidt, Intestinal lavage in the treatment of Crohn's disease: a pi[INVESTIGATOR_799]. Klin Wochenschr, 1982. 60(7): p. 371-3. 24. Wellmann, W., P.C. Fink, and F.W. Schmidt, Whole-gut irrigation as antiendotoxinaemic therapy in inflammatory bowel disease. Hepatogastroenterology, 1984. 31(2): p. 91-3. 25. O'Brien, C.L., et al., Impact of colonoscopy bowel preparation on intestinal microbiota. PLoS One, 2013. 8(5): p. e62815. 26. Prantera, C., et al., An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol, 1996. 91(2): p. 328-32. 27. Sutherland, L., et al., Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut, 1991. 32(9): p. 1071-5. 28. Ursing, B., et al., A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology, 1982. 83(3): p. 550-62. 29. McKenna, P., et al., The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathogens, 2008. 4(2): p. 8. 30. Shieh, F.K., et al., MiraLAX-Gatorade bowel prep versus GoLytely before screening colonoscopy: an endoscopic database study in a community hospi[INVESTIGATOR_307]. J Clin Gastroenterol, 2012. 46(10): p. e96-e100. 31. Hyams, J.S., et al., Development and validation of a pediatric Crohn's disease activity index.  J Pediatr Gastroenterol Nutr, 1991.  12(4): p. 439-47 32. Harvey, R.F. and Bradshaw, J.M., A simple index of Crohn’s-dease activity. The Lancet, 1980, March 8: p. 514. 33. Vermeire, S., et al., Correlation between the Crohn’s Disease Activity and Harvey–Bradshaw Indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol, 2010. 8(4): p. 357-363. 34. Thia, K., et al., Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis, 2011. 17(1): p. 105-11. 35. Vermeire, S., G. Van Assche, and P. Rutgeerts, Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut, 2006. 55: p. 436-31. 36. Roseth, A.G., et al., Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scandinavian Journal of Gastroenterology, 1992. 27(9): p. 793-8. 
   
   48 37. Roseth, A.G., E. Aadland, and K. Grzyb, Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2004. 39(10): p. 1017-20. 38. Roseth, A.G., et al., Assessment of disease activity in ulcerative colitis by [CONTACT_371141], a novel granulocyte marker protein. Digestion, 1997. 58(2): p. 176-80. 39. Walkiewicz, D., et al., Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflammatory Bowel Diseases, 2008. 14(5): p. 669-673. 40. Roseth, A.G., et al., Assessment of disease activity in ulcerative colitis by [CONTACT_371141], a novel granulocyte marker protein. Digestion, 1997. 58(2): p. 176-80. 41. Lin, J.F., et al., Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis, 2014. 20(8): p. 1407-15. 42. Sipponen, T., et al., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis, 2008. 14(10): p. 1392-8. 43. Caporaso, J.G., et al., QIIME allows analysis of high-throughput community sequencing data. Nat Methods, 2010. 7(5): p. 335-6. 44. Su, C., et al., A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology, 2004. 126(5): p. 1257-69. 45. Sandborn, W.J., et al., Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med, 2007. 146(12): p. 829-38. 46. Sandborn, W.J., et al., Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med, 2013. 369(8): p. 711-21. 47. Lozupone, C., M. Hamady, and R. Knight, UniFrac--an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformatics, 2006. 7(371). 48. Lozupone, C. and R. Knight, UniFrac: a new phylogenetic method for comparing microbial communities. Applied & Environmental Microbiology, 2005. 71(12): p. 8228-35. 49. Ciprofloxacin. Daily Med. U.S. National Library of Medicine, NIH Website. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6b5e68-9cd7-4abd-aa88-296b96686228. Accessed September 8, 2017.  50. Vancomycin (Vancomycin hydrochloride). DailyMed. U.S. National Library of Medicine, NIH Website. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29785dd0-f94f-48b5-9194-b4a796c464ce. Accessed September 8, 2017. 51. Neomycin sulfate. DailyMed. U.S. National Library of Medicine, NIH Web site. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f594cca9-6a73-44f3-9093-67af09567cb8, Accessed September 8, 2017. 52. Diflucan (fluconazole). Daily Med. U.S. National Library of Medicine, NIH Website. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d96ed5-53f3-486c-89b2-f0eb63959a2f. Accessed September 8, 2017.  53. MiraLax™. Drugs@FDA. Food and Drug Administratino Web site. https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20698pi.pdf. Accessed July 13, 2017.  
   
   49  